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A B S T R A C T
Background
Evidence is limited regarding the most effective pharmacological treatment for psychotic depression: combination of an antidepressant
plus an antipsychotic, monotherapy with an antidepressant or monotherapy with an antipsychotic. This is an update of a review first
published in 2005 and last updated in 2009.
Objectives
1. To compare the clinical efficacy of pharmacological treatments for patients with an acute psychotic depression: antidepressant
monotherapy, antipsychotic monotherapy and the combination of an antidepressant plus an antipsychotic, compared with each other
and/or with placebo.
2. To assess whether differences in response to treatment in the current episode are related to non-response to prior treatment.
Search methods
A search of the Cochrane Central Register of Controlled Trials and the Cochrane Depression, Anxiety and Neurosis Group Register
(CCDANCTR) was carried out (to 12 April 2013). These registers include reports of randomised controlled trials from the following
bibliographic databases: EMBASE (1970-), MEDLINE (1950-) and PsycINFO (1960-). Reference lists of all studies and related reviews
were screened and key authors contacted.
Selection criteria
All randomised controlled trials (RCTs) that included participants with acute major depression with psychotic features, as well as RCTs
consisting of participants with acute major depression with or without psychotic features, that reported separately on the subgroup of
participants with psychotic features.
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Data collection and analysis
Two review authors independently extracted data and assessed risk of bias in the included studies, according to the criteria of the
Cochrane Handbook for Systematic Reviews of Interventions. Data were entered into RevMan 5.1. We used intention-to-treat data. For
dichotomous efficacy outcomes, the risk ratio (RR) with 95% confidence intervals (CIs) was calculated. For continuously distributed
outcomes, it was not possible to extract data from the RCTs. Regarding the primary outcome of harm, only overall dropout rates were
available for all studies.
Main results
The search identified 3659 abstracts, but only 12 RCTs with a total of 929 participants could be included in the review. Because of
clinical heterogeneity, few meta-analyses were possible. The main outcome was reduction of severity (response) of depression, not of
psychosis.
We found no evidence for the efficacy of monotherapy with an antidepressant or an antipsychotic.
However, evidence suggests that the combination of an antidepressant plus an antipsychotic is more effective than antidepressant
monotherapy (three RCTs; RR 1.49, 95% CI 1.12 to 1.98, P = 0.006), more effective than antipsychotic monotherapy (four RCTs;
RR 1.83, 95% CI 1.40 to 2.38, P = 0.00001) and more effective than placebo (two identical RCTs; RR 1.86, 95% CI 1.23 to 2.82, P
= 0.003).
Risk of bias is considerable: there were differences between studies with regard to diagnosis, uncertainties around randomisation and
allocation concealment, differences in treatment interventions (pharmacological differences between the various antidepressants and
antipsychotics) and different outcome criteria.
Authors’ conclusions
Psychotic depression is heavily understudied, limiting confidence in the conclusions drawn. Some evidence indicates that combination
therapy with an antidepressant plus an antipsychotic is more effective than either treatment alone or placebo. Evidence is limited for
treatment with an antidepressant alone or with an antipsychotic alone.
P L A I N L A N G U A G E S U M M A R Y
Pharmacological treatment for psychotic depression
Psychotic depression is a severe depression with psychotic features (i.e. delusions and/or hallucinations). Uncertainty surrounds themost
effective drug treatment for psychotic depression: with an antidepressant alone, with an antipsychotic alone or with the combination
of an antidepressant plus an antipsychotic.
The aim of this review is to compare the efficacy of the various forms of drug treatment that have been used to treat psychotic depression.
We did this by analysing all randomised controlled trials (RCTs) that investigated drug treatments for psychotic depression. We searched
for these trials in a wide-ranging way. The search identified 3659 studies, but in the end, we found only 12 RCTs that met our inclusion
criteria. These trials involved a total of 929 people.
From these trials, we found evidence that the combination of an antidepressant plus an antipsychotic provides more effective treatment
for psychotic depression than either treatment alone. However, our confidence in this conclusion is limited because the information
came from only a small number of RCTs, which included small numbers of people. In addition, the types of people involved varied
between RCTs, and the RCTs differed in design, which means that we cannot confidently generalise their findings.
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B A C K G R O U N D
Description of the condition
Psychotic depression is a severe condition that is defined as a de-
pressive episode with psychotic features (i.e. delusions and/or hal-
lucinations) in the context of a (unipolar) major depressive disor-
der. Psychotic depression is not uncommon. In the US Epidemio-
logic Catchment Area Study (Johnson 1991), 14% of participants
who met the criteria for major depression had a history of episodes
with psychotic features. In a European general population study,
18.5% of respondents with a major depressive episode had psy-
chotic features; the prevalence of psychotic depression was 0.4%
and of non-psychotic depression 2.0% (Ohayon 2002). In a US
study of hospitalised participants with major depression, 25%met
the criteria for psychotic depression (Coryell 1984). Compared
with non-psychotic depression, psychotic depression is marked by
greater severity, increased incapacity, a lower likelihood of placebo
response, longer duration of episodes and recurrence of psychotic
features in subsequent episodes (Coryell 1998).
Description of the intervention
Guidelines (APA 2010; NICE 2009) recommend electroconvul-
sive therapy (ECT) or pharmacotherapy as treatment for psychotic
depression. Pharmacotherapy for psychotic depression could con-
sist of an antipsychotic, an antidepressant or a combination of
both. Most guidelines recommend treatment that combines an
antidepressant with an antipsychotic (APA 2010; NICE 2009.
However, discussion continues regarding whether the combina-
tion of an antipsychotic plus an antidepressant is more effective
than monotherapy with an antidepressant or an antipsychotic
( Dutch Guideline 2009; Mahli 2009; Parker 1992; Wijkstra
2005; Wijkstra 2007). The intervention studied in this review
is pharmacological treatment for psychotic depression, especially
the question of whether the combination of an antipsychotic plus
an antidepressant is more effective than either treatment given as
monotherapy.
How the intervention might work
All antidepressants enhance the activity of serotonin and/or no-
radrenaline, and some of them (also) dopamine (Sadock 2009).
Most antidepressants achieve this via inhibition of reuptake of
these neurotransmitters in the presynaptic neuron (tricyclic an-
tidepressants (TCAs), selective serotonin reuptake inhibitors (SS-
RIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs)),
although some antidepressants have other working mechanisms
(e.g. blockade of postsynaptic serotonin-2 receptors such as mir-
tazapine or inhibition of their breakdown via inhibition of the
enzyme monoamine oxidase (MAOIs)). Nevertheless, their nora-
drenergic and serotonergic effects do not completely explain their
efficacy, as these effects occur already within hours after first in-
take, but it takes days to weeks before antidepressants begin to ex-
ert their effects in participants with depression or anxiety (Sadock
2009).
Almost all antipsychotics (classical as well as atypical antipsy-
chotics, with the exception of clozapine) are blockers of the postsy-
naptic dopamine-2 receptor, and their therapeutic efficacy is corre-
latedwith their affinity for dopamine-2 receptors in vivo.However,
other effects may contribute to their efficacy, such as their affinity
for presynaptic serotonin-1 receptors, postsynaptic serotonin-2 re-
ceptors and histamine receptors, as can be seen with some atypical
antipsychotics (e.g. olanzapine and quetiapine). Similar to the an-
tidepressants, these effects do not completely explain their efficacy
because they also occur already within hours after first intake, but
it takes days to weeks for antipsychotics to begin to work (Sadock
2009).
The traditional view is that antidepressants work against depres-
sion and antipsychotics work against psychosis. Therefore, it seems
appropriate in psychotic depression to treat the psychotic symp-
toms with an antipsychotic and the depressive symptoms with
an antidepressant. However, when psychotic depression is consid-
ered as the most severe form of depression, and when psychosis is
viewed as the distal consequence of that severity (as is the case in
the Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision (DSM-IV-TR); APA 2000), treatment with
an antidepressant alone seems logical. On the other hand, treat-
ment with an antipsychotic alone, especially one of the newer atyp-
ical antipsychotics with possibly antidepressant effects, cannot be
ruled out.
Why it is important to do this review
Clinical practise is characterised by uncertainty as to whether it
is most appropriate to start treatment in this patient group with
antidepressant monotherapy or with the combination of an an-
tidepressant and an antipsychotic because of the potential adverse
effects of antipsychotics (especially extrapyramidal side effects, hy-
perprolactinaemia and the risk of metabolic syndrome, including
weight gain). A previous meta-analysis did not find a statistically
significant difference between TCA monotherapy and combina-
tion therapy (Parker 1992).However, the findings and conclusions
of that meta-analysis were limited by the inadequate methodology
of many of the included studies, which were often retrospective,
uncontrolled and/or not randomised. Some international guide-
lines on the pharmacological treatment of psychotic depression
(in the United States: Nelson 1997; in the Netherlands: Dutch
Guideline 2009) and those presented in reviews (Wheeler 2000)
suggest that one may consider TCA monotherapy before adding
an antipsychotic. However, in contrast, the American Psychiatric
Association (APA) Practice Guideline for the Treatment of Pa-
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tients with Major Depressive Disorder (APA 2010) and the Na-
tional Institute for Health and Clinical Excellence (NICE 2009)
recommend initial combination therapy. The same recommenda-
tion is made in a review by Coryell (Coryell 1998). This variation
between guidelines reflects the limited evidence on which these
guidelines are based. In a review about evidence used in practice
guidelines (Wijkstra 2007), we concluded that physicians (and pa-
tients) should be aware that guidelines for treatment recommen-
dations may be less evidence-based than asserted, even when it is
stated that treatment recommendations are based on the highest
level of evidence.
Treatment with a classical antipsychotic alone is not recom-
mended, primarily because of the findings of a study by Spiker
(Spiker 1985), in which treatment with perphenazine alone was
less effective than treatment with perphenazine plus amitriptyline.
However, the atypical antipsychotics may be worth reconsidering
now because of the reduced risk of extrapyramidal side effects and
potential antidepressant properties of some of the atypical antipsy-
chotics (Rothschild 2004a).
This review is an update of our Cochrane review first published
in 2005 (Wijkstra 2005). Our conclusion in 2005 was as follows:
”Treatmentwith an antipsychotic alone is not a good option. Start-
ing with the combination of an antidepressant and an antipsy-
chotic, as well as starting with an antidepressant alone and adding
an antipsychotic if the patient does not respond, both appear to
be appropriate options for patients with psychotic depression.”
Since 2005, a few more studies have been conducted, leading to
a different conclusion regarding treatment with an antidepressant
alone or with the combination of an antidepressant and an an-
tipsychotic.
Another important clinical issue is that differences in response to
specific treatments may be explained in relation to non-response
to prior treatment(s). Generalising from observations across med-
ical disciplines, it would be expected that patients who did not
respond to an adequate treatment will respond less to subsequent
treatment. Some data are available on this topic with regard to
pharmacological treatment of major depressive disorder (Sackeim
2001). Two studies (Prudic 1990; Prudic 1996) showed that a
greater degree of treatment resistance predicts an inferior response
to ECT.
O B J E C T I V E S
1. To compare the clinical efficacy of pharmacological
treatments for patients with an acute psychotic depression:
antidepressant monotherapy, antipsychotic monotherapy and the
combination of an antidepressant plus an antipsychotic,
compared with each other and/or with placebo.
2. To assess whether differences in response to treatment in the
current episode are related to non-response to prior treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) of the pharma-
cological treatment of participants with acute psychotic depres-
sion.
As we expected to identify very few RCTs assessing the treatment
of psychotic depression as the primary focus, we decided a priori to
also include RCTs assessing the treatment ofmajor depressionwith
or without psychotic features. Effects in the subgroup of partici-
pants with psychotic features should then be reported separately,
irrespective of whether the subgroup with psychotic features was
stratified before randomisation.
No language restrictions were applied for included studies.
Types of participants
Participants were of any age in any setting (both inpatients and
outpatients) who had a major depressive disorder and a current
episode with psychotic features (delusions and/or hallucinations
appearing in the context of a full major depressive episode) ac-
cording to the Diagnostic and Statistical Manual of Mental Disor-
ders, Third Edition (DSM-III)/DSM,Third Edition, Revised (DSM-
III-R)/DSM, Fourth Edition (DSM-IV)/DSM, Fourth Edition, Text
Revision (DSM-IV-TR) (APA 1980; APA 1987; APA 1994; APA
2000) or International Classification of Diseases (ICD) codes for the
same.
We also included studies in which participants had comorbidities,
as comorbidity was not a reason for exclusion.
As patients with a major depressive episode in the context of a
bipolar disorder (bipolar depression) are at increased risk of switch-
ing to mania (Licht 2008), we intended to include only trials
that assessed participants with unipolar depression. If trials had
included participants with both unipolar and bipolar depression,
we decided a priori to include the trial only when results in the
unipolar group were reported separately, or when the percentage
of participants with bipolar depression did not exceed 20% of the
total study population.
Types of interventions
We included any pharmacological treatment of a current (i.e.
acute) episode. Treatment had to be given for at least four weeks
with the intention of treating the current episode.
Where possible, the following pairwise comparisons were consid-
ered.
1. Antidepressant versus placebo.
2. Antipsychotic versus placebo.
3. Antidepressant versus antidepressant.
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4. Antipsychotic versus antipsychotic.
5. Antidepressant versus antipsychotic.
6. Antidepressant plus antipsychotic versus placebo.
7. Antidepressant plus antipsychotic versus placebo plus
antidepressant.
8. Antidepressant plus antipsychotic versus placebo plus
antipsychotic.
Types of outcome measures
Primary outcomes
1. Efficacy: clinical response of depression based on observer-
rated symptom reduction: reduction of at least 50% on the
Hamilton Rating Scale for Depression (HRSD, Hamilton 1960)
or the Montgomery Åsberg Depression Rating Scale (MADRS,
Montgomery 1979) or any other observer depression severity rat-
ing scale, or a change score on the Clinical Global Impression-
Change (CGI-C, Guy 1976) of ’much improved’ or ’very much
improved’.
2. Harm: overall dropout rate during acute treatment as a proxy
measure of overall acceptability of treatment.
Secondary outcomes
3. Remission of depression as defined in the reports and based on
HRSD or MADRS or other observer depression severity rating
scale.
4. Change from baseline in score on the HRSD, MADRS or any
other observer depression severity rating scale or change in severity
on Clinical Global Impression-Severity (CGI-S).
5. Quality of life, as defined in the reports.
6. Dropout rate due to adverse effects.
Search methods for identification of studies
CCDAN’s Specialised Register (CCDANCTR)
The Cochrane Depression, Anxiety and Neurosis Group (CC-
DAN) maintains two clinical trials registers at its editorial base in
Bristol, UK; a references register and a studies-based register. The
CCDANCTR-References Register contains over 31,500 reports
of trials in depression, anxiety and neurosis. Approximately 65%
of these references have been tagged to individual, coded trials.
The coded trials are held in the CCDANCTR-Studies Register
and records are linked between the two registers through the use
of unique Study ID tags. Coding of trials is based on the EU-
Psi coding manual. Reports of trials for inclusion in the Group’s
registers are collated from routine (weekly), generic searches of
MEDLINE, EMBASE and PsycINFO; quarterly searches of the
Cochrane Central Register of Controlled Trials (CENTRAL) and
review specific searches of additional databases. Reports of trials
are also sourced from international trials registers c/o the World
HealthOrganization’s trials portal (ICTRP), drug companies, and
the handsearching of key journals, conference proceedings and
other (non-Cochrane) systematic reviews and meta-analyses. De-
tails of CCDAN’s generic search strategies can be found on the
Group’s website.
Electronic searches
The CCDANCTR-Studies Register was searched (all years to 12
April 2013) using the following terms:
Condition = (depressi* or “affective disorder*” or “affective symp-
toms”)
AND
Condition or Comorbidity = (psychosis or psychoses or psychotic*
or delusion*)
The CCDANCTR-Studies Register was searched (all years to 12
April 2013) using the following terms to identify additional un-
tagged references:
Title/Abstract/Keywords = ((depressi* or “affective disorder*” or
“affective symptoms”)
AND
Free-Text=(psychosis or psychoses or psychotic* or delusion* or
hallucin* or antipsychotic* or psychotropic*))
An additional search of the Cochrane Central Register of Con-
trolled Trials (CENTRAL) was carried out (Issue 4, 2010)
(Appendix 1).
A summary of searches carried out for the earlier version of this
review can be found in Appendix 2.
Searching other resources
The reference lists of all studies, related reviews and relevant con-
ference proceedings were screened and key authors contacted.
Data collection and analysis
Selection of studies
In step 1, all abstracts of identified publications were screened
independently by two review authors (JL and JW), and studies
were selected if they met the following criteria.
1. RCT.
2. Included participants with a major depressive disorder.
3. Investigated the efficacy of pharmacological treatment.
4. Concerned acute phase treatment (minimum of four weeks
treatment), not continuation or maintenance treatment.
If any doubt or disagreement arose between the review authors,
the publication was included in step 2. Full articles were obtained
for the selected abstracts.
In step 2, selected full articles were screened (JL and JW) according
to the following criteria.
1. Participants with psychotic depression were not excluded.
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2. Results in the subgroup of psychotic depressed participants
were reported separately.
If any doubt arose about the article, it was included in step 4.
In step 3, the reference lists of related reviews and of included
publications, conference abstracts and personal communications
were searched.
Finally, in step 4, two review authors (JL and JW) independently
reviewed all identified publications according to the full inclusion
criteria of the review. Any disagreement was resolved by consensus
discussion with another review author (WN).
Data extraction and management
Extracted data included the following: participant characteristics
(age, gender, setting: inpatients/outpatients); diagnosis (which di-
agnostic instrument, system of classification, number of bipolar
participants); prior treatment of the current episode; intervention;
length of illness; suicide attempts; treatment details (treatment pe-
riod, washout period, additional medication, blood levels, doses)
and outcomemeasures. Data were extracted independently by two
review authors (JW and JL).
All data (from 2004 and recent data) were entered into RevMan
5.1 (RevMan 2011).
Assessment of risk of bias in included studies
In the original version of this review, we assessed methodologi-
cal quality of included studies by criteria set out in the Cochrane
Handbook for Systematic Reviews of Interventions (Alderson 2004);
however, after publication of the revised and expanded Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
we updated ourmethods accordingly.Working independently, JW
and JL assessed risk of bias of included studies using the tool de-
scribed in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011). The following items were assessed.
1. Sequence generation: Was the allocation sequence
adequately generated?
2. Allocation concealment: Was allocation adequately
concealed?
3. Blinding of participants, personnel and outcome assessors
for each main outcome or class of outcomes: Was knowledge of
the allocated treatment adequately prevented during the study?
4. Incomplete outcome data for each main outcome or class of
outcomes: Were incomplete outcome data adequately addressed?
5. Selective outcome reporting: Were reports of the study free
of suggestion of selective outcome reporting?
6. Other sources of bias: Was the study apparently free of
other problems that could put it at high risk of bias?
We included quotations from the text of included studies and
comments on how we assessed the risk of bias; we judged each
study to be of low, unclear or high risk of bias.
See risk of bias figures (Figure 1; Figure 2).
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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If disputes arose as towhich judgement should be given, resolution
was achieved after consultationwith the third review author (WN).
Measures of treatment effect
Binary outcomes
For binary efficacy outcomes, such as response, remission and
dropouts, the risk ratio (RR) (with 95%confidence intervals (CIs))
was calculated for each comparison using the numbers randomly
assigned and the numbers of events.
Continuous outcomes
For continuously distributed outcomes, we calculated the stan-
dardised mean difference (SMD).
Skewed and non-quantitative outcome data were presented de-
scriptively.
Unit of analysis issues
We identified neither cluster-randomised nor cross-over trials.
However, if found, we would not have included them in our re-
view, as we were interested in differences not between clusters (e.g.
clinics) but between drugs or classes of drugs; nor were we inter-
ested in the results of a cross-over phase, as the outcome of the first
phase might have had an impact on the outcome of the second
(i.e. cross-over) phase.
In case a study had multiple intervention groups, only the data for
the pairwise comparison in question were included. Further, if a
study compared two or more medications of the same type (e.g.
venlafaxine and imipramine), data were combined into a single
category, for example, the category ’antidepressant’.
Dealing with missing data
We used intention-to-treat (ITT) response data in the analyses, as
ITT data are less biased and because they address amore pragmatic
and clinically relevant question (Higgins 2011). When necessary,
we converted response data from the trials into ITT response data
by using the total number of randomly assigned participants per
group that had started with treatment as the denominator. So
participants who had started with medication but were withdrawn
before endpoint were assumed not to have experienced response.
Whendataweremissing,we contacted the study authors to request
the required data.
No other imputation techniques were used to deal with missing
data.
Assessment of heterogeneity
First, we evaluatedwhether clinical homogeneity could be assumed
by evaluating any between-study dissimilarities regarding partic-
ipants, interventions and outcome measures. Studies that were
considered to threaten the clinical homogeneity assumption were
excluded from the meta-analysis.
The I2 statistic supplied with a 95% CI was used to assess the
magnitude of statistical heterogeneity when values exceeding 0.40
were considered possibly relevant. We did not perform the Q test
to determine heterogeneity because of its low power in our meta-
analysis resulting from the low numbers of studies in all of our
comparisons.
Pre-stated subgroup analyses were planned to explore sources of
any heterogeneity. No meta-regression was performed.
Assessment of reporting biases
When data from at least 10 studies became available, the presence
of publication bias was assessed using contour-enhanced funnel
plots in which treatment effects expressed as RR (Relative Risk)
from individual studies were plotted against each study’s sample
size. We did not perform Egger’s regression test in view of low
statistical power in our meta-analyses, again resulting from the low
number of studies included.
It must be noted that asymmetry of funnel plots does not necessar-
ily indicate publication bias but may result from other biases such
as inflated results in smaller studies due to poorer methodological
quality, or true heterogeneity.
Data synthesis
We primarily used the Mantel-Haenszel fixed-effect method to
calculate pooled risk ratios with 95% confidence intervals. Risk
ratios are preferred over odds ratios because of their more straight-
forward interpretation (i.e. the number of times the outcome is
more likely to occur given one treatment over another).
In cases in which evidence of statistical heterogeneity was
found, we used DerSimonian and Laird’s random-effects models
(DerSimonian 1986).
Subgroup analysis and investigation of heterogeneity
If sufficient data were available, subgroup analyses were planned
as follows.
1. Participants who were non-refractory to prior treatment(s)
during the current episode.
2. Participants with mood congruent psychotic features only.
Because all psychotically depressed patients are considered to be
severely depressed, it was not considered appropriate to evaluate
baseline severity in a subgroup analysis.
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Sensitivity analysis
If sufficient data were available, sensitivity analyses were planned
as follows.
1. Studies focusing on psychotic depression only.
2. Studies in which participants with psychotic depression
were separately randomised.
3. Studies of lower methodological quality to assess robustness
of results.
4. Smaller versus larger studies.
R E S U L T S
Description of studies
Results of the search
In 2004 from the Cochrane Central Register of Controlled Tri-
als (CENTRAL) search, we identified 1782 publications: in the
searches in MEDLINE 720 and in EMBASE 831; in total, 3333.
With some overlap from 2004, we have since found an addi-
tional 326 publications. The first step of screening the abstracts
of these publications in 2004 resulted in 798 relevant publica-
tions (749 from CENTRAL, 38 from MEDLINE and 11 from
EMBASE); in 2011, we found 40 additional studies (three from
CENTRAL, 32 from CCDANCTR-References Register and 5
from CCDANCTR-Studies Register). The second step of screen-
ing the full articles of these publications in 2004 resulted in the
identification of 52 publications (47, three and two respectively)
and now 17 (one from CENTRAL, 13 from CCDANCTR-Ref-
erences Register and three from CCDANCTR-Studies Register).
In 2004, handsearching of reference lists from relevant reviews re-
sulted in the identification of one other publication (Bellini 1994),
and handsearching of the included publications did not lead to
identification of any further relevant publications. Now, this re-
sulted in no publications. In 2004, the final fourth step of review-
ing these 53 publications resulted in seven included studies, and
in 2004 we added two other publications, which we knew were in
press: one by van den Broek (van den Broek 2004a) and one re-
porting two similar trials (Rothschild 2004a; Rothschild 2004b).
Thus, in 2004 in total, nine publications with 10 RCTs were in-
cluded. Now, in the fourth step, by reviewing 17 publications, we
found two additional studies to be included.
In additional searches on the CCDANCTR and CENTRAL (De-
cember 2011 to April 2013), we found another 288 references.
Of these 288 references, we did not find any other publication to
include.
So, taking together both searches, we found 3974 publications
through the electronic search strategies, from which we finally
included 11 publications with 12 RCTs (see Figure 3).
9Pharmacological treatment for psychotic depression (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 3. Study flow diagram.
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In 2004, 13 studies needed a consensus discussion in the fourth
step of the search strategy before they were excluded, and now
five additional studies needed such a discussion before they were
excluded, resulting in a total of 18 excluded studies (see Excluded
studies).
Included studies
See the table Characteristics of included studies for a description
of the 12 included RCTs (Anton 1990; Bruijn 1996;Meyers 2009;
Mulsant 2001; Rothschild 2004a; Rothschild 2004b; Spiker 1985;
Spiker 1988; Zanardi 1996; Zanardi 2000; van den Broek 2004a;
Wijkstra 2010).
Design
All studies were RCTs comparing the effects of pharmacological
interventions for the treatment of psychotic depression or for the
treatment of depression with and without psychotic features but
with data about the participants with psychotic features published
separately.
Sample sizes
Sample sizes were as follows: Anton 1990: 46; van den Broek
2004a: 48; Bruijn 1996: 30;Mulsant 2001: 54; Rothschild 2004a:
124; Rothschild 2004b: 125; Spiker 1985: 58; Spiker 1988: 27;
Zanardi 1996: 32; Zanardi 2000: 22; Meyers 2009: 259; and
Wijkstra 2010: 122, for a total of 947 participants,
Setting
In most studies, inpatients were included, except Meyers 2009,
Rothschild 2004a and Rothschild 2004b. In Meyers 2009, 69.1%
of participants entered as inpatients. In the studies of Rothschild,
participants were treated for at least one week as inpatients.
Seven of the studies originate from the United States, three from
the Netherlands (Bruijn 1996; van den Broek 2004; Wijkstra
2010) and two from Italy (Zanardi 1996; Zanardi 2000).
Participants
All participants fulfilled criteria for major depressive disorder with
psychotic features, classified according to a formal classification
system (RDC: Research Diagnostic Criteria, DSM-III, DSM-IV,
DSM-IV-TR). Six studies explicitly used a semi-structured diag-
nostic interview (van den Broek 2004a: SADS: Schedule for Affec-
tive Disorders and Schizophrenia; Bruijn 1996: SADS; Mulsant
2001: BPRS: Brief Psychiatric Rating Scale; Spiker 1985: SADS;
Meyers 2009: SCID IV: Structured Clinical Interview for DSM-
IV; Wijkstra 2010: SCID IV).
Diagnostic procedures were different between the studies. In all
studies, participants were diagnosed according to a formal classifi-
cation system (RDC, DSM-III, DSM-IV, DSM-IV-TR). Six stud-
ies explicitly used a semi-structured diagnostic interview (van den
Broek 2004a: SADS; Bruijn 1996: SADS; Mulsant 2001: BPRS;
Spiker 1985: SADS;Meyers2009: SCIDIV;Wijkstra 2010: SCID
IV). These different procedures could have led to possible differ-
ences in participant categories.
Seven studies included only participants with unipolar psychotic
depression. In the study of Zanardi 1996, it was possible to exclude
bipolar participants from the data. In the study of Anton 1990,
15.8% (six out of thirty eight) bipolar participants were included
in the data that the author used in his analysis. However, it was
unclear how many of the eight dropouts, who were excluded be-
fore analysis, were bipolar participants. The author was not able
to give additional information. Therefore, we decided to assume
a random dropout rate. In the study of Spiker 1985, 15.5% of
participants were bipolar (Anton 1990; Spiker 1985). In the stud-
ies of Bruijn 1996 and Zanardi 2000, we were able to exclude the
bipolar participants with additional information provided by the
authors. In the studies of Bruijn 1996, Meyers 2009 and Wijkstra
2010, the types of psychotic symptoms were described in greater
detail. In Spiker 1985, only participants with mood congruent
delusions were included. This indicates some heterogeneity in di-
agnosis with regard to bipolarity.
Interventions
1. Antidepressant versus placebo was studied in one study (Spiker
1988): amitriptyline (three weeks at least 150 mg) versus placebo;
treatment period was four weeks.
2. Antipsychotic versus placebo was the subject in one arm of the
two identical studies of Rothschild (Rothschild 2004a; Rothschild
2004b): olanzapine (mean 11.9 mg; respectively, 14.0 mg) versus
placebo; treatment period was eight weeks.
3. Antidepressant versus antidepressant was examined in five stud-
ies. In van den Broek 2004: imipramine (plasma levels imipramine
plus its metabolite desmethylimipramine 192 to 521 ng/mL) ver-
sus fluvoxamine (plasma level 109 to 325 ng/mL); treatment pe-
riod was four weeks after predefined blood levels were reached;
in Bruijn 1996: imipramine (plasma levels imipramine plus its
metabolite desmethylimipramine 199 to 400 ng/mL) versus mir-
tazapine (plasma level 49 to 93 ng/mL); treatment period was
four weeks after predefined blood levels were reached; in Zanardi
1996: sertraline (150 mg from day eight) versus paroxetine (50
mg from day eight); treatment period was five weeks; in Zanardi
2000: venlafaxine (300 mg from day eight) versus fluvoxamine
(300 mg from day eight); treatment period was five weeks; and in
one arm of the study of Wijkstra 2010: imipramine (plasma levels
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imipramine plus its metabolite desmethylimipramine 200 to 300
ng/mL) versus venlafaxine (375 mg); treatment period was seven
weeks.
4. Antipsychotic versus antipsychotic was not available in any
study.
5. Antidepressant versus antipsychotic was the subject in one arm
of the study by Spiker 1985: amitriptyline (mean dose 218 mg;
130 to 500 ng/mL) versus perphenazine (mean dose 50 mg; blood
level 19 to 113 ng/mL); treatment period was four weeks.
6. Antidepressant plus antipsychotic versus placebo was studied in
one armof both identical studies of Rothschild (Rothschild 2004a;
Rothschild 2004b): olanzapine (12.4 mg; respectively, 13.9 mg)
plus fluoxetine (23.5 mg; respectively, 22.6 mg) versus placebo;
treatment period was eight weeks.
7. Antidepressant plus antipsychotic versus placebo plus antide-
pressant was studied in four studies. In Anton 1990: amitripty-
line (150 to 250 mg) plus perphenazine (24 to 40 mg) versus
amoxapine (300 to 500 mg); treatment period was four weeks;
in Mulsant 2001: nortriptyline (mean 63 mg) plus perphenazine
(mean 19 mg) versus nortriptyline (mean dose 76 mg); treatment
started with nortriptyline, and once nortriptyline blood level was
between 50 and 50 ng/mL, random assignment followed; treat-
ment period with nortriptyline plus perphenazine (or placebo) af-
ter random assignment was 2 to 16 weeks (total treatment at least
four weeks); in one arm of the study by Spiker 1985: amitriptyline
(mean 170 mg; 18 to 128 ng/mL) plus perphenazine (mean 54
mg; 157 to 690 ng/mL) versus amitriptyline (mean 218 mg; 130
to 500 ng/mL); treatment period was four weeks; and in two arms
of Wijkstra 2010: venlafaxine (375 mg) plus quetiapine (600 mg)
versus imipramine (plasma levels imipramine plus its metabolite
desmethylimipramine 200 to 300 ng/mL) and versus venlafaxine
(375 mg); treatment period was 7 weeks.
8. Antidepressant plus antipsychotic versus placebo plus antipsy-
chotic was the subject in three studies. In one arm of both identi-
cal studies of Rothschild (Rothschild 2004a; Rothschild 2004b):
olanzapine (12.4 mg; respectively, 13.9 mg) plus fluoxetine (23.5
mg; respectively, 22.6 mg) versus olanzapine (mean 11.9 mg; re-
spectively, 14.0 mg); treatment period was eight weeks; in one
arm of Spiker 1985: amitriptyline (mean 170 mg; 18 to 128 ng/
mL) plus perphenazine (mean 54 mg; 157 to 690 ng/mL) versus
perphenazine (mean dose 50 mg; blood level 19 to 113 ng/mL);
treatment period was four weeks; and in Meyers 2009, olanzapine
(15 to 20 mg) plus sertraline (150 to 200 mg) versus olanzapine
(15 to 20 mg); treatment period was 12 weeks.
Most of these studies had a washout period before the start of
treatment or random assignment, varying from four to seven days.
One study had a washout period of two weeks (Spiker 1988). Be-
cause of the design of the study of Mulsant 2001 (all participants
used nortriptyline before random assignment to additional per-
phenazine or placebo), this study was considered a trial without a
washout period. The two trials Rothschild 2004a and Rothschild
2004b had a ’screening period’ of three to nine days, leaving un-
clear whether this was a period in which medication was not al-
lowed. In Meyers 2009, psychotropics were tapered before ran-
dom assignment without a washout period. So, heterogeneity is
seen in the medication-free period before treatment.
Dosage of psychotropics used in the different trials was consid-
ered reasonably adequate. However, differences in dosing strate-
gies led to possible bias. In four studies re TCAs, doses were ad-
justed according to predefined therapeutic plasma levels (Bruijn
1996;Mulsant 2001; van den Broek 2004a;Wijkstra 2010). In the
study of Spiker 1985, dose adjustment was not based on plasma
levels, but afterwards it was found that the plasma levels were
therapeutic in most participants, although plasma levels of partic-
ipants receiving TCAs alone were lower compared with those of
participants receiving TCA plus antipsychotic. In the two other
trials with TCAs, no plasma levels were determined. Dosages in
the Spiker 1988 study were at least 150 mg/d, but only during
three of the four study weeks. In the study of Anton 1990, partic-
ipants received at least 150 mg/d from the third day of the four-
week study period. Amitriptyline 150 mg/d is in the low range
of an adequate dosage. In the studies of van den Broek 2004 and
Bruijn 1996, SSRIs (fluvoxamine and mirtazapine) were dosed ac-
cording to predefined plasma levels. Fixed doses were used in the
studies of Zanardi (Zanardi 1996; Zanardi 2000): sertraline 150
mg, paroxetine 50 mg, venlafaxine 300 mg and fluvoxamine 300
mg. In the studies of Rothschild (Rothschild 2004a; Rothschild
2004b), doses were clinically adjusted: olanzapine 5 to 20 mg and
fluoxetine 20 to 80 mg.
Differences in additional medication strategies were also noted.
In most studies, additional medication was used, such as benzo-
diazepines (flurazepam up to 30 mg or lorazepam as needed) and
anticholinergics. In the studies of van den Broek 2004a and Bruijn
1996, some participants were treated with additional haloperidol,
if clinically needed. With information provided by the authors,
we were able to identify these participants in the results, and we
counted them as dropouts, as in these studies the focus was the
comparison of two antidepressants.
Outcomes
The primary efficacy outcome was the response rate in each study.
It was not possible to transfer the authors’ defined response data
into rates based on one definition (i.e. at least 50% reduction of
the HRSD score). Some authors used response definitions based
on what is often considered remission. In addition, some authors
included psychotic symptoms in their response definition. In the
absence of a better option, we decided to use the response data as
reported by the authors.
Differences in outcome measures were noted. In most trials, the
HRSD was used as an outcome measure. However, different ver-
sions of the HRSD were used, and the authors used different def-
initions of response. In six trials, the response definition was a re-
duction of at least 50%of theHRSD score comparedwith baseline
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(Anton 1990; Bruijn 1996; Rothschild 2004a; Rothschild 2004b;
van den Broek 2004; Wijkstra 2010). In four studies, the authors’
definition of response was actually comparable with a frequently
used definition of remission (Spiker 1985; Spiker 1988; Zanardi
1996; Zanardi 2000).
In five studies, the response definition also includes psychotic
symptoms (Meyers 2009; Mulsant 2001; Spiker 1985; Zanardi
1996; Zanardi 2000). Bruijn 1996 and van den Broek 2004a
used a response criterion of HRSD-17 < 50%; Anton 1990 ≤
50%; Rothschild 2004a and Rothschild 2004b HRSD-24 < 50%;
Wijkstra 2010 < 50% plus < 15; Spiker 1985 HRSD-17 < 7 and
no delusions; Spiker 1988 HRSD-17 < 7 and not psychotic, or
HRSD-17 6.5 to 9.5 and not psychotic and a third less of entering
score; and Mulsant 2001 HRSD-17 < 11 and BPRS score of the
items 11, 12 and 15 of 1 or 2 (i.e. not psychotic). In Meyers 2009,
remission was defined as HRSD-17 score < 11 and no psychosis;
Zanardi 1996 HRSD-21 < 8 and DDERS (Dimensions of Delu-
sional Experience Rating Scale) = 0; and Zanardi 2000 HRSD-21
< 9 and DDERS = 0. In the studies of Zanardi 1996 and Zanardi
2000, no minimum HRSD score was applied as an inclusion cri-
terion.
In addition to response rates based on the above criteria used
by study authors, several studies reported remission rates sepa-
rately (van den Broek 2004a: HRSD-17 < 8, Rothschild 2004a
and Rothschild 2004b: HAMD-24 < 9 for two consecutive visits,
Wijkstra 2010: HRSD-17 < 8). In two studies, the authors’ defi-
nition of response is the same as what is nowadays considered the
definition of remission (Spiker 1985 and Spiker 1988: HRSD-17
< 7).
Dropout rates
Overall dropout rates for the primary outcome were available
for all studies. Dropout rates due to adverse effects were avail-
able for six studies (Anton 1990; Meyers 2009; Mulsant 2001;
Spiker 1985; van den Broek 2004a;Wijkstra 2010).Dropout rates
due to adverse effects were not based on ITT analysis for three
studies (Bruijn 1996; Rothschild 2004a; Rothschild 2004b); were
unavailable for one study (Spiker 1988); and were the same as
the overall dropout rates for two studies (Zanardi 1996; Zanardi
2000). Dropouts specifically due to mortality or suicide were not
reported, so we decided to extract only overall dropout rates.
The overall dropout rates for the studies varied from 9% to 45%.
In the Bruijn 1996 study, the reported dropout rate was 10%.
However, when haloperidol-treated participants were included as
dropouts, as was our approach, the dropout rate was 40%. In
the two multicenter trials with olanzapine/fluoxetine (Rothschild
2004a; Rothschild 2004b), dropout rates were 41%, and even
higher non-completion rates (56%) were reported. Mostly, no sta-
tistically significant differences in overall dropout rates were noted
between any of the treatments, neither in individual studies nor
after pooling of studies.
Prior treatment
The Bruijn 1996 study provided information on prior treatment
of the current episode. However, these data were not available for
the subgroup with psychotic depression. In Wijkstra 2010, some
data about prior treatment are available. The other studies did not
provide information on prior treatment of the current episode.
Therefore, it was not possible to examine differences in treatment
response in relation to non-response to prior treatment(s).
Excluded studies
See the Characteristics of excluded studies table.
Reasons for exclusion involved not fulfilling inclusion criteria:
open study design, problems with diagnosis (unclear diagnostic
procedure, more then 20% bipolar participants included and no
additional data to exclude bipolar participants), low numbers of
included participants (3 to 15 per group), problems with treat-
ments (continuation of mood stabilisers, treatment with diverse
psychotropics), no possibility to extract ITT data and no adequate
data on the MDD subgroup.
Risk of bias in included studies
See Figure 1 and Figure 2 and the table Characteristics of included
studies.
Allocation
All included studies were randomised studies. Randomisation was
fully described in van den Broek 2004a and Wijkstra 2010. Ran-
domisation was described in part in Meyers 2009, Spiker 1985
and Spiker 1988. In the other eight studies, randomisation was
mentioned as such, but the methods of randomisation were not
delineated.
(Random sequence generation: seven studies unclear risk and five
low risk of bias; allocation concealment: 10 unclear risk and two
low risk.)
Blinding
All studies were double-blind studies, but blinding itself was not
always adequately described in the methods section of the study.
Blinding was adequately described in Anton 1990, Bruijn 1996,
Meyers 2009, Mulsant 2001, Spiker 1985, Spiker 1988, van den
Broek 2004a and Wijkstra 2010. The method of blinding was
not explicitly described in Rothschild 2004a, Rothschild 2004b,
Zanardi 1996 and Zanardi 2000. However, the authors explicitly
state the double-blind condition of their studies; we have no reason
to doubt that these double-blind conditions pertained to both
investigators/assessors and participants.
(Blinding of participants: two studies unclear risk and 10 studies
low risk; blinding of personnel: two studies unclear risk and 10
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studies low risk; blinding of outcome assessors: five studies unclear
risk and seven studies low risk.)
Incomplete outcome data
The primary efficacy outcome was the response rate (of depres-
sion). It was not possible to transfer the authors’ defined response
data into rates based on a single definition (i.e. 50% reduction of
the HRSD score). Some authors used response definitions based
on what is often considered remission (e.g. HAMD < 8 or 10),
and some authors included psychotic symptoms in their response
definition. In the absence of a better option, we decided to use
response data as reported by the authors, with the preference to
use response of depression rather than response of psychosis.
In eight of the 12 studies, we recalculated intention-to-treat re-
sponse rates using all randomly assigned participants as the de-
nominator. Of 46 participants in the study of Anton 1990, eight
were dropped from the study before receiving two full weeks of ac-
tive medication. These participants were excluded from the analy-
sis by the author, but we included them in our ITT analysis. In the
studies of van den Broek 2004a and Bruijn 1996, we counted par-
ticipants treated with haloperidol as dropouts because haloperidol
treatment in these participants was started after random assign-
ment, in part to keep them in the study. Thus, treatment with
haloperidol is considered a potential bias with regard to the ef-
fect of study medication as well as dropout. Mulsant 2001 ex-
cluded six dropouts after random assignment to perphenazine or
placebo. We included them in our ITT analysis. In the studies of
Rothschild 2004a and Rothschild 2004b, seven per cent and nine
per cent, respectively, of randomly assigned participants were lost
before baseline plus one visit. These participants were excluded
from the study’s analysis but were included in our ITT analysis. In
both studies of Spiker (Spiker 1985; Spiker 1988), seven dropouts
were excluded from their analysis, but we included them in our
ITT analysis.
For the secondary outcome of change in symptom severity, we de-
cided to refrain from using continuous data from observer depres-
sion severity scales. In two studies (Bruijn 1996; van den Broek
2004), continuous data were available for the total group (psy-
chotic and non-psychotic) but not from the psychotic subgroup.
In four studies, continuous data were not available (Anton 1990;
Mulsant 2001; Spiker 1988; Zanardi 1996). In one study (Spiker
1985), baseline and final mean HRSD data are given, but it was
impossible to exclude bipolar participants from these data and con-
vert the data to ITT data. In the studies of Rothschild (Rothschild
2004a; Rothschild 2004b), only LOCF continuous data are avail-
able, and in this study, dropout is very high. Pooling of data from
the three remaining studies is useless because three different com-
parisons are studied: AD versus AD (Zanardi 2000) with no ITT
data; AD + AP versus AP (Meyers 2009); and AD + AP versus AD
(Wijkstra 2010).
(Incomplete data: one study high risk, three studies unclear risk
and eight studies low risk.)
Selective reporting
All studies used generally accepted outcomes. From two recent
studies (Meyers 2009 and Wijkstra 2010), the study protocol is
available; in these two studies, no post-protocol changes in out-
come measures had been made (except in Wijkstra 2010, which
used remission as an outcome not stated in the protocol but with
reasonable argument that remission has become a generally ac-
cepted outcome measure).
(Selective reporting: 10 studies unclear risk and two studies low
risk.)
Other potential sources of bias
The subgroup of psychotic depressed participants (Bruijn 1996;
Spiker 1988; van den Broek 2004a) was not stratified before ran-
dom assignment in any of these studies. Subgroup analysis are
more likely to be carried out if the results for primary outcomes
are not significant or are more likely to be reported for groups for
whom a significant result was found. However, in the case of this
review, we ourselves analysed subgroup data in studies that pri-
marily reported on participants with depression with and without
psychotic features.
As described under ’Description of included studies’, clinical het-
erogeneity is seen within the results.
In five studies, response definition included responsewith regard to
psychotic symptoms (Meyers 2009; Mulsant 2001; Spiker 1985;
Zanardi 1996; Zanardi 2000), and in the other studies (Anton
1990; Bruijn 1996; Rothschild 2004a; Rothschild 2004b; Spiker
1988; van den Broek 2004; Wijkstra 2010; Zanardi 1996), re-
sponse rates concerned only change in severity of depression. In
our analysis, we looked only for response of depression leading to
a possible bias favouring antidepressants over antipsychotics.
(Other biases together: seven studies high risk and five studies
unclear risk.)
Effects of interventions
For the secondary outcome of change in symptom severity, extract-
ing continuous data from observer depression severity scales was
not possible because in seven studies, we were not able to convert
these data according to intention-to-treat analysis (Anton 1990;
Bruijn 1996 ; Rothschild 2004a; Rothschild 2004b; Spiker 1985;
Spiker 1988; van den Broek 2004a), and in two other studies, no
continuous data were reported (Zanardi 1996; Zanardi 2000).
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Comparison 1. Antidepressant versus placebo
Primary outcomes
1.1 Efficacy response rates
An antidepressant was compared with placebo in only one study.
In this study (Spiker 1988; Analysis 1.1), no evidence suggested
that amitriptyline was superior to placebo (RR 8.40, 95% CI 0.50
to 142.27, P = 0.14).
1.2 Harm: overall dropout rate during acute treatment





1.4 Change from baseline
No ITT data.
1.5 Quality of life
No data,
1.6 Dropout rate due to adverse effects
No data.
Comparison 2. Antipsychotic versus placebo
Primary outcomes
2.1 Efficacy response rates
Two studies compared an antipsychotic with placebo (Rothschild
2004a; Rothschild 2004b). Pooling of these studies (Analysis 2.1)
does not reveal a difference between olanzapine and placebo (RR
1.13, 95% CI 0.74 to 1.73, P = 0.57).
2.2 Harm: overall dropout rate during acute treatment
Pooling of these two studies (Rothschild 2004a; Rothschild 2004b;





2.4 Change from baseline
For the secondary outcome of change in symptom severity, ex-
tracting continuous data from observer depression severity scales
was not possible; we were not able to convert these data according
to ITT analysis (Rothschild 2004a; Rothschild 2004b).
2.5 Quality of life
No data.
2.6 Dropout rate due to adverse effects
No data.
Comparison 3. Antidepressant versus antidepressant
Primary outcomes
3.1 Efficacy response rates
In five studies, two different antidepressants were compared di-
rectly with each other (Bruijn 1996; van den Broek 2004a;
Wijkstra 2010; Zanardi 1996; Zanardi 2000).
Differences in efficacy were found in three of these studies. In
the study by van den Broek 2004a (Analysis 3.1), imipramine
was more effective than fluvoxamine (RR 2.10, 95% CI 1.06 to
4.17); in the study by Bruijn 1996 (Analysis 3.1), imipramine was
near more effective than mirtazapine (RR 3.00, 95% CI 1.01 to
8.95); and in the study by Zanardi 1996 (Analysis 3.1), sertraline
was better than paroxetine (RR 3.37, 95% CI 1.19 to 9.57, P =
0.02). The study by Zanardi 2000 (Analysis 3.1) did not reveal a
difference between fluvoxamine and venlafaxine (RR 1.50, 95%
CI 0.82 to 2.75). In Wijkstra 2010 (Analysis 3.1), no difference
was noted between imipramine and venlafaxine (RR 1.57, 95%
CI 0.93 to 2.67).
Pooling of studies was not reasonable because different antidepres-
sants were used.
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3.2 Harm: overall dropout rate during acute treatment





3.4 Change from baseline
Pooling not possible because different antidepressants were used.
3.5 Quality of life
No data.
3.6 Dropout rate due to adverse effects
No data.
Comparison 4. Antipsychotic versus antipsychotic
No data were available for any outcome for this comparison.
Comparison 5. Antidepressant versus antipsychotic
Primary outcomes
5.1 Efficacy response rates
We found one RCT that compared an antidepressant with an an-
tipsychotic. In this trial (Spiker 1985; Analysis 4.1), no difference
between perphenazine and amitriptyline was reported (RR 2.09,
95% CI 0.64 to 6.82).
5.2 Harm: overall dropout rate during acute treatment
One study (Spiker 1985; Analysis 4.2) reported no difference be-





5.4 Change from baseline
For the secondary outcome of change in symptom severity, ex-
tracting continuous data from observer depression severity scales
was not possible because in the only study, we were not able to
convert these data according to intention-to -treat analysis (Spiker
1985).
5.5 Quality of life
No data.
5.6 Dropout rate due to adverse effects
No data.
Comparison 6. Antidepressant plus antipsychotic
versus placebo
Primary outcomes
6.1 Efficacy response rates
Two identical studies (Rothschild 2004a; Rothschild 2004b) com-
pared the combination of fluoxetine and olanzapine with placebo.
Pooling of the studies (Analysis 5.1) reveals the combination to
more efficacious (RR 1.86, 95% CI 1.23 to 2.82, P = 0.003).
6.2 Harm: overall dropout rate during acute treatment
Pooling of both studies (Rothschild 2004a; Rothschild 2004b;
Analysis 5.2) reveals no difference (RR 0.75, 95%CI 0.48 to 1.18,
P = 0.21).
In this pooling, we find heterogeneity (I2 = 76%). In these two
studies, dropout rates are high-in one study higher for placebo,




6.4 Change from baseline
For the secondary outcome of change in symptom severity, extract-
ing continuous data from observer depression severity scales was
not possible because in these two studies, we were not able to con-
vert these data according to intention-to -treat analysis (Rothschild
2004a; Rothschild 2004b).
16Pharmacological treatment for psychotic depression (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
6.5 Quality of life
No data.
6.6 Dropout rate due to adverse effects
No data.
Comparison 7. Antidepressant plus antipsychotic
versus placebo plus antipsychotic
Primary outcomes
7.1 Efficacy response rates
Four studies compared the combination of an antidepressant plus
an antipsychotic with antipsychotic monotherapy (Meyers 2009;
Spiker 1985; Rothschild 2004a; Rothschild 2004b).
In the ITT analysis of Spiker et al. (Spiker 1985; Analysis 6.1),
the combination of amitriptyline plus perphenazine was superior
to perphenazine (RR 3.61, 95% CI 1.23 to 10.56, P = 0.02).
Pooling of both identical Rothschild studies (Analysis 6.1;
Rothschild 2004a; Rothschild 2004b) gives an advantage to the
combination of olanzapine plus fluoxetine over olanzapine alone
(RR 1.64, 95% CI 1.10 to 2.44, P = 0.01).
In Meyers at al (Meyers 2009; Analysis 6.1), olanzapine plus ser-
traline was more effective than olanzapine alone (RR 0.57, 95%
CI 0.39 to 0.82, P = 0.003).
Pooling the data from all four studies (Meyers 2009; Rothschild
2004a; Rothschild 2004b; Spiker 1985; Analysis 6.1) shows a dif-
ference favouring the combination (RR 1.83, 95% CI 1.40 to
2.38, P = 0.00001).
7.2 Harm: overall dropout rate during acute treatment
Pooling all four studies (Meyers 2009; Rothschild 2004a;
Rothschild 2004b; Spiker 1985; Analysis 6.2) reveals no difference
(RR 0.79, 95% CI 0.63 to 1.01, P = 0.06, I2 = 63%).
Heterogeneity of these pooled results is possibly a result of the
Rothschild 2004a and Rothschild 2004b studies because in these
two studies, dropout rates are very high, and these rates are differ-




7.4 Change from baseline
For the secondary outcome of change in symptom severity, ex-
tracting continuous data from observer depression severity scales
was not possible because in three studies, we were not able to
convert these data according to ITT analysis (Rothschild 2004a;
Rothschild 2004b; Spiker 1985).
7.5 Quality of Life
No data.
7.6 Dropout rate due to adverse effects
No data.
Comparison 8. Antidepressant plus antipsychotic
versus placebo plus antidepressant
Primary outcomes
8.1 Efficacy response rates
Four studies (five comparisons) compared the combination of
an antidepressant plus an antipsychotic with antidepressant
monotherapy (Anton 1990;Mulsant 2001; Spiker 1985;Wijkstra
2010). Two of these studies compared aTCAplus an antipsychotic
with TCA monotherapy (Mulsant 2001; Spiker 1985). Pooling of
the ITT data of these two studies (as in our first review) did not
reveal a difference (RR 1.44, 95% CI 0.86 to 2.41, P = 0.16: anal-
ysis in first review). Another study that compared the combination
of venlafaxine plus an antipsychotic (quetiapine) with venlafaxine
monotherapy and with imipramine monotherapy (Wijkstra 2010;
Analysis 7.1) found a difference with venlafaxine (RR 0.51, 95%
CI 0.31 to 0.83) but not with imipramine (RR 0.80, 95% CI
0.55 to 1.14). In the study of Anton 1990, amoxapine was used
as an antidepressant with antipsychotic effects. Pooling of these
five studies results in a difference favouring the combination (RR
1.42; 95% CI 1.11 to 1.80, P = 0.002; Analysis 7.1).
Three studies in this comparison used the same antidepressant in
both arms, whereas two studies used a different antidepressant in
each arm. Analysing just the studies where the same antidepressant
was used in both arms (i.e. leaving out Anton 1990 and Wijkstra
2010) (Analysis 8.1) still reveals a difference in favour of the com-
bination (RR 1.70, 95% CI 1.19 to 12.43, P = 0.003).
8.2 Harm: overall dropout rate during acute treatment
No differences were noted after pooling of these three studies (
Analysis 7.2): RR 0.91, 95% CI 0.55 to 1.50, P = 0.69. In the
subgroup analysis, no difference is noted (Analysis 8.2; RR 1.04,
95% CI 0.52 to 0.91, P = 0.91).
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8.4 Change from baseline
For the secondary outcome of change in symptom severity, ex-
tracting continuous data from observer depression severity scales
was not possible because we were not able to convert these data
according to intention-to-treat analysis.
8.5 Quality of life
No data.
8.6 Dropout rate due to adverse effects
No data.
Subgroup and sensitivity analysis
Because of lack of data, subgroup and sensitivity analyses were not
possible.
D I S C U S S I O N
Despite our extensive search of the literature (screening more than
3600 abstracts and 829 full articles, as well as carefully reviewing
69 publications), we identified very few RCTs on pharmacological
treatment with an antidepressant, an antipsychotic or the com-
bination of an antidepressant with an AP of participants with a
major depressive disorder with a current episode with psychotic
features (unipolar psychotic depression).
In addition to nine studies, whose main focus was the treatment of
participants with psychotic depression, we were able to find three
studies that reported separately on the effects of the subgroups of
participants with psychotic depression. The authors of two further
studies provided us with additional information on the results
for the subgroup of psychotically depressed participants in their
studies on both psychotic and non-psychotic depressed patients.
In our previous review, we invited authors of several studies to
provide us with subgroup data if available, so we could use these
data in our review, but we did not receive any data.
In this update, we found two new studies to be added to the ten
studies found in our previous review, which (again) illustrates that
this most severe form of depression is highly under-investigated.
One probable reason for this is that it is very difficult to conduct
RCTs in patients with psychotic depression. These patients of-
ten are not only psychotic but are very anxious or physically ill.
Moreover, they are often offered ECT directly without a trial of
pharmacological treatment. Finally, many patients with psychotic
depression are not able or are reluctant to give informed consent,
or they tend to withdraw their consent.
As a result of the paucity of RCTs, few clinically relevant conclu-
sions can be drawn.
Summary of main results
1. Evidence was derived from two identical placebo-controlled
studies (Rothschild 2004a; Rothschild 2004b; Analysis 5.1) for
the efficacy of the combination of an antidepressant plus an an-
tipsychotic (fluoxetine plus olanzapine vs placebo; RR 1.86, 95%
CI 1.23 to 2.82, P = 0.003)
2. We found evidence that the combination of an antidepres-
sant plus an antipsychotic is more effective than antidepressant
monotherapy. Pooling of four studies (five comparisons) that com-
pared the combination of an antidepressant plus an antipsychotic
with antidepressant monotherapy (Anton 1990; Mulsant 2001;
Spiker 1988; Wijkstra 2010; Analysis 7.1) results in a significant
difference favouring the combination (RR 1.42, 95% CI 1.11 to
1.80, P = 0.002). When the two comparisons with a different an-
tidepressant are left out (Anton 1990; Wijkstra 2010), this differ-
ence still is statistically significant (Analysis 8.1; RR 1.70, 95% CI
1.19 to 2.43, P = 0.003). In our previous review, based on two
studies (Mulsant 2001; Spiker 1988; RR 1.44, 95% CI 0.86 to
2.41), no such proof was found. Therefore, it can be concluded
that the recommendation in the APA guidelines (APA 2010) that
in psychotic depression the combination should be preferred over
an AD alone can be considered evidence based.
3. The combination of an antidepressant plus an antipsychotic is
more effective than antipsychotic monotherapy. Pooling of four
studies that compared the combination of an antidepressant plus
an antipsychotic with antipsychotic monotherapy (Meyers 2009;
Rothschild 2004a; Rothschild 2004b; Spiker 1985; Analysis 6.1)
shows a difference favouring the combination (RR 1.83, 95% CI
1.40 to 2.38, P = 0.00001). This confirms the conclusion stated in
our previous reviewbased on three of these four studies (Rothschild
2004a; Rothschild 2004b; Spiker 1985).
4. No randomised controlled data are available to lead to the con-
clusion that an antidepressant alone is efficacious in the treat-
ment of psychotic depression. Only one small study compared
monotherapy with an antidepressant (amitriptyline) with placebo
(Spiker 1988; Analysis 1.1) and reported no difference (RR 8.40,
95% CI 0.50 to 142.27).
5. No randomised controlled data are available to lead to the con-
clusion that an antipsychotic alone is efficacious in the treatment
of psychotic depression. Two studies comparedmonotherapy with
an antipsychotic (olanzapine) with placebo (Rothschild 2004a;
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Rothschild 2004b). Pooling of these two studies does not reveal a
difference (Analysis 2.1; RR 1.13, 95% CI 0.74 to 1.73).
6.Wewere not able to collect data on prior treatments. Sowe could
not address the second objective of our review: to assess whether
differences in response to treatment in the current episode would
be related to non-response to prior treatment(s).
7. Regarding acceptability of treatment (dropout, adverse effects)
and quality of life, we were able to collect data only on overall
dropout. In all studies except the study of Meyers 2009, no dif-
ferences in overall dropout rates were reported between any of the
treatment groups, neither in individual studies nor after pooling
of studies. With this rather rough measure, we did not find overall
differences in overall acceptability of treatments. In the study of
Meyers 2009, fewer dropouts were reported in the group treated
with the combination of olanzapine plus sertraline than in the
group treated with olanzapine alone (RR 1.43, 95% CI 1.08 to
1.88). The authors suggest that higher attrition rates among partic-
ipants treated with olanzapine plus sertraline may be attributable
to insufficient response in the olanzapine-treated group.
8. We only found indication of heterogeneity drop-out data in
instanceswhere the two identical studies of Rothschild (Rothschild
2004a; Rothschild 2004b) were included (Analysis 2.2; Analysis
5.2; Analysis 6.2). This heterogeneity probably is due to high
dropout rates, together with differences in dropout rates between
the two studies.
Overall completeness and applicability of
evidence
Our conclusions are based on only 12 studies that fulfilled our
inclusion criteria. Moreover, in the included studies, only a few
different antidepressants and antipsychotics were used. Therefore,
it remains unclear whether the above conclusions can be extrap-
olated to other antidepressants and antipsychotics. Strictly spo-
ken, evidence that the combination of an antidepressant plus an
antipsychotic is more effective than an antidepressant alone in an
RCT has been obtained only for the combination of venlafaxine
and quetiapine compared with venlafaxine (Wijkstra 2010), al-
though evidence that the combination of an antidepressant plus
an antipsychotic is more effective than an antipsychotic alone has
been obtained in RCTs for only two antipsychotics: the combi-
nation of amitriptyline and perphenazine reported as more effec-
tive than perphenazine (Spiker 1985); all three other studies in-
volved combinations with olanzapine: in two studies with fluoxe-
tine (Rothschild 2004a; Rothschild 2004b) and in one study with
sertraline (Meyers 2009).
Nearly all participants in these studies were inpatients. This of
course is a consequence of the severity of the illness and the fact
that in clinical practice, most patients with psychotic depression
are treated as inpatients. There is also the problem of patients who
were not included in the studies: the most severely ill patients who
were not able to give informed consent or who were immediately
given ECT. All these points limit the generalisability of the results
to all patients with psychotic depression.
These problems with the quality of diagnostic assessment can re-
strict generalisation of the findings to all patients with psychotic
depression, leaving aside the problem of establishing the diagnosis
of psychotic depression in clinical reality.
Quality of the evidence
The strength of this review and its conclusion is that only ran-
domised controlled studies have been included, and only ITT data
have been used in the analyses.
Several factors limit our confidence in the findings of this review.
Most studies were relatively small. Only four RCTs had a more or
less adequate sample size: Rothschild 2004a; Rothschild 2004b:
with olanzapine 48 and 53 participants, with placebo 51 and 49
participants, but only 25 and 23 olanzapine plus fluoxetine, re-
spectively; Meyers 2009: with olanzapine + sertraline 129 and
sertraline 130 participants; and Wijkstra 2010: imipramine 42,
venlafaxine 39 and venlafaxine + quetiapine 41 participants. As
with all systematic reviews, publication bias is a potentially serious
source of bias. Too few studies were identified to allow further in-
vestigation into the possibility of publication bias (e.g. by making
funnel plots). However, the fact that in these mostly small trials,
five (50%) found a significant difference between two active treat-
ments, is suggestive of publication bias.
Allocation concealment, especially in the older studies, was not
explicitly described. Although we do not assume allocation con-
cealment to be a real bias, this is of course unsure.
Dosages of antidepressants and antipsychotics used in the different
trials were considered reasonably adequate. However, differences
in dosing strategies were noted, leading to possible bias. Differ-
ences in additional medication strategies and differences in treat-
ment periods were also reported (see paragraph ’Other potential
sources of bias’).
We could use only one outcome measure regarding efficacy: the
response rates as defined by the authors. It was impossible to recal-
culate these response rates into a standard response rate based on a
single definition (e.g. reduction on the HRSD-17 of at least 50%
compared with baseline), as many studies used other versions of
the HRSD. Moreover, some studies used response definitions that
are commonly used for the definition of remission, and we could
not recalculate the results to the more commonly used definition
of response (i.e. reduction of 50% compared with baseline).
We cannot rule out the possibility of differences in the diagnostic
assessment of participants and thus in the quality of the diagnosis
across the studies. Although it was reported in all publications
that participants included in the trials fulfilled criteria for a major
depressive episode with psychotic features, according to a specified
diagnostic classification system (RDC,DSM-III orDSM-IV), one
could doubt the reliability of the diagnoses made in some trials.
Six studies (Bruijn 1996; Meyers 2009; Mulsant 2001; Spiker
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1985; van den Broek 2004;Wijkstra 2010) used a semi-structured
interview, and only three studies (Bruijn 1996; Meyers 2009;
Wijkstra 2010) reported the types of psychotic features. This leaves
open the possibility that for instance the judgement that a feeling
or idea of guilt was a guilt delusion was drawn differently across
the studies in this review. A similar diagnostic problem may have
played a role in the judgement of whether a participant had a
psychotic depression in the course of unipolar disorder or bipolar
disorder. Finally, the study of Mulsant 2001 included a geriatric
sample with a mean age of 72 years, leading to the possibility
that dementia or another neurological disorder was part of the
diagnosis in some participants.
Potential biases in the review process
One problem is that there does not exist a key word (Mesh Term)
for psychotic depression. Therefore, we had to search all RCTs
involving depression on whether included participants had de-
pression with psychotic features, or whether such participants had
been part of the group of included participants and were reported
as a separate subgroup. We anticipated in the first version of this
review that we might have missed one or more studies. However,
we did not receive any information that we had missed any study.
Therefore, in this update, we are now rather sure that we indeed
have included all existing studies.
In three studies (Bruijn 1996; Spiker 1988; van den Broek 2004a),
the subgroup of psychotic depressed participants was part of a
greater group of participants with psychotic and non-psychotic
depression, although the subgroups were not stratified before ran-
dom assignment.
Another potential problem, which was not taken into account in
our a priori protocol before this systematic review was performed,
is that in five studies, the response definition included response
with regard to psychotic symptoms (Meyers 2009; Mulsant 2001;
Spiker 1985; Zanardi 1996; Zanardi 2000), although in the other
studies (Anton 1990; Bruijn 1996; Rothschild 2004a; Rothschild
2004b; Spiker 1988; van den Broek 2004;Wijkstra 2010; Zanardi
1996), response rates concerned only change in severity of depres-
sion. In our analysis, we looked only for the response of depres-
sion, leading to a possible bias favouring antidepressants over an-
tipsychotics.
Agreements and disagreements with other
studies or reviews
In a review of practice guidelines regarding the treatment of psy-
chotic depression (Wijkstra 2007), we found different recommen-
dations based on slightly different studies, mostly not reanalyzed.
Two guidelines-Nice 2004 and the Dutch guideline 2005 (now
updated with no changes regarding treatment of psychotic depres-
sion: Dutch Guideline 2009; NICE 2009)-were cautious in their
recommendations. Nice 2004: Augmenting an AD with an AP
should be considered; and Dutch 2005: Starting treatment with a
TCA and if after 4 weeks there is still no response, adding an AP
is a reasonable option; starting with the combination of a TCA
and an AP is also a reasonable option. The other reviewed guide-
lines, including the APA guideline 2000 (now updated with no
differences regarding the treatment of psychotic depression; APA
2010), recommend using the combination of an AD and an AP.
None of these guidelines recommended monotherapy with an an-
tipsychotic. These recommendations were not based on a system-
atic review of data from all available RCTs; they were based on
a few studies-some randomised and some open non-randomised.
Another meta-analysis on the treatment of psychotic depression
has been published (Farahani 2012). This review and meta-analy-
sis is focused on the comparison of antidepressant or antipsychotic
monotherapy with combination treatment. Five studies were in-
cluded (Anton 1990; Künzel 2008; Mulsant 2001; Spiker 1985;
Wijkstra 2010). In our review, for this particular comparison, we
excluded Künzel 2008 because it is unclear whether less or more
than 20% of included participants in the ITT group had a bipo-
lar disorder (see table Excluded studies), and we did not use the
study of Anton 1990 because we did not regard amoxapine as an
antidepressant (Analysis 8.1). We included in our review the same
three other studies (Mulsant 2001; Spiker 1985; Wijkstra 2010),
using exactly the same extracted ITT data. The conclusion of this
review is consistent with ours: Combination treatment is more
effective than antidepressant monotherapy. For the comparison of
an antipsychotic plus an antidepressant versus an antipsychotic,
the same four studies with again exactly the same extracted ITT
data were included (Meyers 2009; Rothschild 2004a; Rothschild
2004b; Spiker 1985; Analysis 5.1), leading in both reviews to the
same conclusion: Combination treatment is more effective than
antipsychotic monotherapy. As in our review, no differences were
reported in overall dropout rates across all studies for both com-
parisons.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Psychotic depression is heavily under-studied, limiting confidence
in the conclusions drawn. Evidence suggests that combination
therapy with an antidepressant plus an antipsychotic is more ef-
fective than either treatment alone or placebo. Evidence for treat-
ment with an antidepressant alone or for an antipsychotic alone is
lacking.
Implications for research
Further studies are needed:
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1. to study the efficacy of other combinations of an
antidepressant plus an antipsychotic. Regarding the
antidepressants: combinations with a TCA, with an SSRI or with
other newer antidepressants such as mirtazapine; regarding the
antipsychotics: combinations with other so called atypical
antipsychotics (aripiprazole, risperidone, olanzapine, etc.);
2. to compare the effect of the combination of an
antidepressant with antipsychotics with other pharmacological
options, such as the augmentation of an antidepressant with
lithium or more experimental treatments such as ketamine;
3. to compare the effect of the combination of an
antidepressant plus an antipsychotic with ECT; and
4. to evaluate the efficacy of stepwise approaches or algorithms
encompassing the previous steps after each other.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anton 1990
Methods Randomised, double-blind comparison
Participants No explicit use of structured interview
DSM-III criteria; psychotic depressive episode
HRSD 17 > 18
Inpatients.
No data about prior treatment of current episode
Interventions Amoxapine versus amitriptyline + perphenazine.
300 to 500 mg versus 150 to 250 mg + 24 to 40 mg
No blood levels
Five days placebo period. Additional medication in these five days: lorazepam or ox-
azepam in ’low dose’
Treatment period: four weeks. Additional medication is not mentioned in these four
weeks
Outcomes Dichotomous data: author defined: Response is reduction of HRSD-17 > 50%. No
remission data
Continuous data: symptom reduction: no ITT data; global response: no ITT data; QOL:
no data
Overall dropout rate: yes
Dropout due to adverse effects: yes (two in ami + per)
Mortality rate: 0
Notes 56 participants provided informed consent. 10 dropped out in washout before receiving
active medication (four refused and six improved substantially); 46 participants were
randomly assigned
46 participants: four dropouts in both groups (total eight). Unclear how many bipolar
participants among these eight dropouts; 38 participants were analysed, including six
bipolar participants
6/38 bipolar = 15.8%
ITT responders: amoxapine 12/21 and ami + per 17/25 (instead of 12/17 and 17/21)
Dropouts after random assignment: 9/21 and 7/25
Author had no additional data available
See also 1993 J Aff Disorders 28:125-131 (same data set)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk As reported: ’Patients were randomly assigned
in a double blind fashion’
Allocation concealment (selection bias) Unclear risk No information
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Anton 1990 (Continued)
Blinding (performance bias and detection
bias)
of participants
Low risk As reported: ’Double blind treatment with
identical capsules’
Blinding (performance bias and detection
bias)
of personnel
Low risk As reported: ’Double blind treatment with
identical capsules’
Blinding (performance bias and detection
bias)
of outcome assessors
Unclear risk Probably yes. No explicit data
Incomplete outcome data (attrition bias)
All outcomes
High risk 46 participants were randomly assigned. In
the publication, only those participants who
completed at least two weeks of active medi-
cation were analysed. Four dropouts in both
groups (total eight)
Selective reporting (reporting bias) Unclear risk No protocol available. Generally accepted
outcomes have been used
Other bias High risk Unclear how many bipolar participants were
present among these eight dropouts; 38 par-
ticipants were analysed, including six bipolar
participants. 6/38 bipolar = 15.8%. No addi-
tional data available to exclude bipolar partic-
ipants from reanalysis
We reanalyzed the data with ITT respon-
ders (intention-to-treat; dropouts included):
amoxapine 12/21 and ami + per 17/25 (in-
stead of 12/17 and 17/21). ITT dropouts af-
ter random assignment: 9/21 and 7/25
Bruijn 1996
Methods Randomised, double-blind comparison
Participants Use of checklist with DSM-III-R criteria
SADS depression portion was performed in the presence of a second psychiatrist
DSM-III-R depressive episode; excluded psychotic depression with hallucinations
HRSD-17 > 17
Inpatients. Subgroup psychotic depression. Probably only with delusions
51% of included participants were adequately pretreated during the current episode:
adequate dose of an antidepressant during at least four weeks
Interventions Imipramine versus mirtazapine; 37.5 to 450 mg imipramine (blood level: 199 to 400
ng/mL) versus 40 to 100 mg mirtazapine (blood level 49 to 93 ng/mL)
Washout: three days medication free and four days placebo
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Bruijn 1996 (Continued)
Additional medication: one to six tablets a day containing 45 mg of an extract of valerian,
lorazepam 1 to 5 mg a day or haloperidol 1 to 15 mg a day
Treatment period: four weeks after predefined blood levels reached (mirtazapine group:
five to 21 days; imipramine group: seven to 25 days)
Outcomes Dichotomous data: author defined: Response is reduction of HRSD-17 ≥ 50%. No
remission data
Continuous data: symptom reduction: no ITT data; global response: no ITT data; QOL:
no data
Overall dropout rate: yes
Dropout due to adverse effects: no ITT data in subgroup
Mortality rate: 0
Notes Worse responding in a group leads to more participants given haloperidol
107 participants included; six bipolar; 10 dropouts
Subgroup: MDD psychotic; 30 (15 mirtazapine and 15 imipramine)
Mirtazapine group: seven haloperidol treatment (six non-responders, one responder)
Imipramine group: two haloperidol treatment (two non-responders)
Participants treated with haloperidol by us counted as dropouts
Mirtazapine group: one dropout + seven haloperidol treatment = 8/18; imipramine
group: two dropouts + two haloperidol treatment = 4/15
Additional information from author included
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk As reported: ’Patients were randomly allo-
cated to a double blind treatment’
Allocation concealment (selection bias) Unclear risk No explicit information
Blinding (performance bias and detection
bias)
of participants
Low risk As reported: ’Identical capsules. Dose adjust-
ment by an independent psychiatrist on the
basis of blood levels’
Blinding (performance bias and detection
bias)
of personnel
Low risk As reported: ’Identical capsules. Dose adjust-
ment by an independent psychiatrist’
Blinding (performance bias and detection
bias)
of outcome assessors
Low risk Side effects were not systematically rated to
prevent bias towards unblinding. After com-
pletion of the study, the research psychiatrist
guessed the medication: 46 correct and 37 in-
correct
Incomplete outcome data (attrition bias)
All outcomes
Low risk None
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Bruijn 1996 (Continued)
Selective reporting (reporting bias) Unclear risk No protocol available. Generally accepted
outcomes have been used
Other bias High risk Participants with psychotic depression with
hallucinations were excluded. So only partic-
ipants with psychotic depression with delu-
sions were included in the reanalyzed sub-
group
We reanalyzed the data in the subgroup
with psychotic depression. We counted as
dropout: one participant with bipolar disor-
der, nine participants with haloperidol treat-
ment (seven in mirtazapine group and two in
imipramine group)
Worse responding in psychotic depression
leads in this study to more open co-treat-
ment with haloperidol 1 to 15 mg, especially
in the mirtazapine group. Only one of these
nine participants (mirtazapine group) was a
responder. So haloperidol probably was not
instrumental in the recovery of those partici-
pants
Meyers 2009
Methods Randomised double-blind study
Participants 259 participants; DSM-IV-TR psychotic depression; 18 years of age or older; HAM-D
>= 21 and SADS delusional severity rating >= 3
Inpatients
Interventions 12 weeks treatment with olanzapine + placebo and olanzapine + sertraline
Outcomes Remission rates (HAM-D 17 <= 10 and SADS delusional item score = 1)
Notes 53% dropout in olanzapine arm and 37% dropout in olanzapine + sertraline arm
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk As reported: ’Computer generated randomisation
list’
Allocation concealment (selection bias) Unclear risk No further data
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Meyers 2009 (Continued)
Blinding (performance bias and detection
bias)
of participants
Low risk Study was double blind (reported as: ’sertraline and
placebo under double-blind conditions’)
Blinding (performance bias and detection
bias)
of personnel
Low risk Well described double blinding. ’Sertraline and
placebounder double-blind conditions’. As reported:
’Investigators and raters were blind to treatment as-
signment’
Blinding (performance bias and detection
bias)
of outcome assessors
Low risk Well described double blinding. ’Sertraline and
placebounder double-blind conditions’. As reported:
’Investigators and raters were blind to treatment as-
signment’
Incomplete outcome data (attrition bias)
All outcomes
Low risk None
Selective reporting (reporting bias) Low risk Protocol available. Generally accepted outcomes
have been used
Other bias Unclear risk Relatively high dropout rate with significant dif-
ference between treatment groups.(53% olanzapine
and 37% olanzapine + sertraline)
Patients with only hallucinations excluded
Mulsant 2001
Methods Randomised, double-blind comparison
Participants Clinical interview, Brief Psychiatric Rating Scale, Global Assessment Scale and a con-
sensus conference were used for diagnosis
DSM-III-R; psychotic major depressive episode (manic episode in history excluded).
HAM-D-17 > 17
Age > 50 years
Inpatients
No data about prior treatment of current episode
Interventions Nortriptyline versus nortriptyline + perphenazine
Open nortriptyline until therapeutic plasma level (target 100 ng/mL); once between 50
and 150 ng/mL, random assignment followed
Mean doses: nortriptyline 76 mg versus nortriptyline 63 mg + perphenazine 19 mg
Mean blood levels: 101 ng/mL versus 120 + 4 ng/mL
Additional medication: lorazepam as needed
Treatment period: after random assignment 2 to 16 weeks (total treatment at least four
weeks)
”After a washout of other psychotropic medication except lorazepam ....” It is unclear
how long this washout has been
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Mulsant 2001 (Continued)
Outcomes Dichotomous data: author defined: Response is HAMD-17 < 11 and BPRS (11, 12, 15)
1 or 2. No remission data
Continuous data: symptom reduction: no ITT data; global response: no ITT data; QOL:
no data
Overall dropout rate: yes
Dropout due to adverse effects: nortriptyline + perphenazine 1/17; nortriptyline +
placebo 2/19
Mortality rate: 0
Notes 54 participants included; 16 dropouts: three improved on nortriptyline, three adverse
effects and nine administrative reasons; 36 participants randomly assigned. This is by
procedure a selected group: responders on nortriptyline and participants with adverse
effects and with other reasons are excluded (28%)
Open nortriptyline (eight to 21 days; median two weeks); once between 50 and 150 ng/
mL, random assignment followed
Responder somewhere between two and 16 weeks after randomisation (median nine
weeks); three dropouts in both groups after random assignment. These are excluded by
the author and included by us for ITT analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information. As reported: ’Patient[s] were
randomly allocated to a double blind treat-
ment’
Allocation concealment (selection bias) Unclear risk No information. As reported: ’Patient[s] were
randomly allocated to a double blind treat-
ment’
Blinding (performance bias and detection
bias)
of participants
Low risk As reported: ’Double blind treatment.No fur-
ther data’
Blinding (performance bias and detection
bias)
of personnel
Low risk ’Dose adjustments by non blinded psychia-
trist who were not involved in the care’
Blinding (performance bias and detection
bias)
of outcome assessors
Low risk As reported: ’Double blind treatment’
Incomplete outcome data (attrition bias)
All outcomes
Low risk None
Selective reporting (reporting bias) Unclear risk No protocol available. Generally accepted
outcomes has been used
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Mulsant 2001 (Continued)
Other bias High risk No outcome data about prescription of ’lo-
razepam as needed’
EPS rating could have led to blinding bias
Participants treated with only nortriptyline (+
placebo) were excluded after four weeks with-
out improvement, and participants treated
with nortriptyline + perphenazine after four
+ two weeks
Rothschild 2004a
Methods Randomised, double-blind comparison
Random assignment was 2:2:1 for olanzapine, placebo and olanzapine fluoxetine com-
bination, respectively
Participants 124 participants; DSM-IV diagnosis (unclear how)
Major depression with psychotic features
Inpatients for at least one week.
No data about prior treatment of current episode
Interventions 2004a: olanzapine (5 to 20 mg, clinically titrated; mean 11.9 mg) versus olanzapine (5
to 20 mg, clinically titrated; mean 12.4 mg) plus fluoxetine (20 to 80 mg, clinically
titrated; mean 23.5 mg) versus placebo
2004b: same procedure: olanzapine (mean 14.0 mg) versus olanzapine (mean 13.9 mg)
plus fluoxetine (mean 22.6 mg)
Three to nine days screening; probably no washout period
Treatment period: eight weeks
Additional medication: 30 mg a day diazepam equivalent for no more than five consec-
utive days or 10 cumulative days
Outcomes Dichotomous data: author defined: Response is reduction of HAMD-24 ≥ 50% at
endpoint. Remission is HAMD-24 ≤ 8 for two consecutive visits
Continuous data: symptom reduction: no ITT data; global response: no ITT data; QOL:
no data
Overall dropout rate: yes
Dropout due to adverse effects: no ITT data
Mortality rate: probably 0
Notes Washout unclear
23 investigators randomly assigned at least one participant. Excluded patient character-
istics not described
Dropouts in study a: 28%; lost before baseline + one visit: 7% (were excluded from
results; included in our data); 24% in study a are LOCF (last observation carried forward;
in our data not counted as dropouts); some of these LOCFs are counted as responders;
total non-completers (LOCF included) 28 + 7 + 24 = 59%
Dropouts in study b: 38%; lost before baseline + one visit: 9% (were excluded from
results; included in our data); LOCF in study b: 6%; total non-completers 28 + 9 + 6 =
53%
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Rothschild 2004a (Continued)
Completers in study a: 41%; in study b: 47%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk As reported: ’Patients were randomly allo-
cated’; no further information
Allocation concealment (selection bias) Unclear risk As reported: ’Patients were randomly allo-
cated’; no further information
Blinding (performance bias and detection
bias)
of participants
Low risk As reported: ’Double blind therapy. Dose
adjustments in all study arms with ’cap-
sules’ (assuming identical capsules because
the study is double blind)’
Blinding (performance bias and detection
bias)
of personnel
Low risk As reported: ’Double blind therapy’
Blinding (performance bias and detection
bias)
of outcome assessors
Unclear risk No explicit information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropouts described in general terms. Very
high dropout rate
Selective reporting (reporting bias) Unclear risk No protocol available. According to the au-
thors, the olanzapine-fluoxetine group was
designed as a exploratory pilot arm. How-
ever, in the conclusions, it is stated that
an olanzapine/fluoxetine combination was
a well-tolerated treatment associated with
significant and quick reduction in depres-
sive (and psychotic) symptoms in one trial.
With ITT data, this difference is seen in
one study to be not statistically significant,
and in the other study barely significant.
Pooling of these two studies would result
in no significance
The authors discuss as a limitation the ab-
sence of a fluoxetine arm. They state that
they cannot rule out that the effect of flu-
oxetine/olanzapine was due to fluoxetine.
So this should have been mentioned in the
conclusion
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Rothschild 2004a (Continued)
Other bias High risk High dropout rate of 34.7% reduces the
internal validity of the study
High placebo response is contradictory to
the literature
Rothschild 2004b
Methods Randomised, double-blind comparison
Random assignment was 2:2:1 for olanzapine, placebo and olanzapine fluoxetine com-
bination, respectively
Participants 124 participants. DSM-IV diagnosis (unclear how)
Major depression with psychotic features
Inpatients for at least one week.
No data about prior treatment of current episode
Interventions 2004a: olanzapine (5 to 20 mg, clinically titrated; mean 11.9 mg) versus olanzapine (5
to 20 mg, clinically titrated; mean 12.4 mg) plus fluoxetine (20 to 80 mg, clinically
titrated; mean 23.5 mg) versus placebo
2004b: same procedure: olanzapine (mean 14.0 mg) versus olanzapine (mean 13.9 mg)
plus fluoxetine (mean 22.6 mg)
Three to nine days screening; probably no washout period
Treatment period: eight weeks
Additional medication: 30 mg a day diazepam equivalent for no more than five consec-
utive days or 10 cumulative days
Outcomes Dichotomous data: author defined: Response is reduction of HAMD-24 ≥ 50% at
endpoint. Remission is HAMD-24 ≤ 8 for two consecutive visits
Continuous data: symptom reduction: no ITT data; global response: no ITT data; QOL:
no data
Overall dropout rate: yes
Dropout due to adverse effects: no ITT data
Mortality rate: probably 0
Notes Washout unclear
23 investigators randomly assigned at least one participant. Excluded patient character-
istics not described
Dropouts in study a: 28%; lost before baseline + one visit: 7% (were excluded from
results; included in our data); 24% in study a are LOCF (last observation carried forward;
in our data not counted as dropouts). Some of these LOCFs are counted as responders;
total non-completers (LOCF included) 28 + 7 + 24 = 59%
Dropouts in study b: 38%; lost before baseline + one visit: 9% (were excluded from
results; included in our data); LOCF in study b: 6%; total non-completers 28 + 9 + 6 =
53%
Completers in study a: 41%; in study b: 47%
Risk of bias
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Rothschild 2004b (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk As reported: ’Patients were randomly allo-
cated’; no further information
Allocation concealment (selection bias) Unclear risk As reported: ’Patients were randomly allo-
cated’; no further information
Blinding (performance bias and detection
bias)
of participants
Low risk As reported: ’Double blind therapy. Dose
adjustments in all study arms with ’cap-
sules’ (assuming identical capsules because
the study is double blind)’
Blinding (performance bias and detection
bias)
of personnel
Low risk As reported: ’Double blind therapy’
Blinding (performance bias and detection
bias)
of outcome assessors
Unclear risk No explicit information
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Dropouts described in general terms. Very
high dropout rate
Selective reporting (reporting bias) Unclear risk No protocol available. According to the au-
thors, the olanzapine-fluoxetine group was
designed as a exploratory pilot arm. How-
ever, in the conclusions, it is stated that
an olanzapine/fluoxetine combination was
a well-tolerated treatment associated with
significant and quick reduction in depres-
sive (and psychotic) symptoms in one trial.
With ITT data, this difference is seen in
one study to be not statistically significant,
and in the other study to be barely signifi-
cant. Pooling of these two studies would re-
sult in no significance. The authors discuss
as a limitation the absence of a fluoxetine
arm. They state that they cannot rule out
that the effect of fluoxetine/olanzapine was
due to fluoxetine. So this should have been
mentioned in the conclusion
Other bias High risk High dropout rate of 47.2% reduces the
internal validity of the study
High placebo response is contradictory to
the literature
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Spiker 1985
Methods Randomised, double-blind comparison
Random assignment procedure described in part
Blinding adequately described
Participants SADS and RDC criteria for major depressive disorder, primary subtype and psychotic
subtype (only with delusions); bipolar participants included
Severity rating 4 or greater on 6-point scale in the SADS that rates severity of delusion
HRSD-17 > 14
Inpatients
No data about prior treatment of current episode
Interventions Three groups: perphenazine versus amitriptyline versus amitriptyline + perphenazine
Doses: perphenazine mean 50mg versus amitriptylinemean 218mg versus amitriptyline
mean 170 mg + perphenazine mean 54 mg
Blood levels: perphenazine 19 to 113 ng/mL versus amitriptyline (+ nortriptyline) 130
to 500 ng/mL versus amitriptyline 157 to 690 ng/mL + perphenazine 18 to 128 ng/mL
Seven days drug free
Treatment period: four weeks
Additional medication: benztropine mesylate 4 mg
Outcomes Dichotomous data: author defined: Response is HRSD-17 < 7 and delusional rating
score = 1 (6-point scale in the SADS). No remission data (definition of response is
definition of remission)
Continuous data: symptom reduction: no ITT data; global response: no ITT data; QOL:
no data
Overall dropout rate: yes
Dropout due to adverse effects: amitriptyline + perphenazine 2/22, perphenazine 1/17
Mortality rate: 0
Notes Only participants with delusions
Seven drop out in ITT (in the original data, dropouts are excluded from the analysis);
response data ITT 3/17 (original 3/16); 7/19 (7/17); 14/22 (14/18)
9/58 = 15.5% bipolar participants in analysis. Because of lack of data, we were not able
to exclude these bipolar participants from the analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk As reported: ’The hospital pharmacist as-
signed patients randomly’
Allocation concealment (selection bias) Low risk Probably yes: ’The hospital pharmacist as-
signed patients randomly’
Blinding (performance bias and detection
bias)
of participants
Low risk As reported: ’The hospital pharmacist as-
signedpatients randomly. All tablets looked
identical’
’All raters and floor staff and the patient
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Spiker 1985 (Continued)
were blind to the patient’s drug treatment
and the plasma-level data’
Blinding (performance bias and detection
bias)
of personnel
Low risk As reported: ’The hospital pharmacist as-
signedpatients randomly. All tablets looked
identical’
’All raters and floor staff and the patient
were blind to the patient’s drug treatment
and the plasma-level data’
Blinding (performance bias and detection
bias)
of outcome assessors
Low risk As reported: ’The hospital pharmacist as-
signedpatients randomly. All tablets looked
identical’
’All raters and floor staff and the patient
were blind to the patient’s drug treatment
and the plasma-level data’
Incomplete outcome data (attrition bias)
All outcomes
Low risk None
Selective reporting (reporting bias) Unclear risk No protocol available. Generally accepted
outcomes have been used
Other bias Unclear risk Only participants with delusions are in-
cluded
9/58 = 15.5% bipolar participants in anal-
ysis. Because of lack of data, we were not
able to exclude these bipolar participants
from the analysis
We reanalyzed the data to ITT
Spiker 1988
Methods Reanalyzing two studies (not including the data of the Spiker 1985 study)
Randomised, double-blind, placebo-controlled
Randomisation procedure not explicitly described
Blinding adequately described in original studies
Participants Re-diagnosing by using DSM-III criteria
Major depressive disorder DSM-III
HRSD-17 > 14 (30 or more based on the sum of two raters)
Inpatients. Subgroup psychotic participants
No data about prior treatment of current episode
Interventions Amitriptyline versus placebo
Three days 50; four days 100; seven days 150, 14 days 200 mg amitriptyline (at least
three weeks ≥ 150 mg)
Blood levels: unknown
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Spiker 1988 (Continued)
Extra medication: none
Two weeks drug-free washout period
One week placebo (single-blind); total period of three weeks drug free
Treatment period: four weeks
Outcomes Dichotomous data: author defined: Response is HRSD-17 < 7 (< 14/2) + not psychotic
or HRSD-17 = 6.5 to 9.5 (13/2 to 19 /2) + not psychotic + 1/3 or less of entering score.
Remission data not specified
Continuous data: symptom reduction: no data; global response: no data; QOL: no data
Overall dropout rate: yes
Dropout due to adverse effects: no data
Mortality rate: 0 (no data)
Notes 20% response in two-week drug-free period (psychotic + non-psychotic); no data about
psychotic versus non-psychotic in these two weeks
Four weeks treatment; only two weeks 200 mg; no blood levels
Subgroup of 27 participants with psychotic depression. Amitriptyline 14; placebo 13
Dropouts four (amitriptyline) and three (placebo) are excluded from analysis by the
authors. Responders amitriptyline 4/10 and placebo 0/10. ITT responders: amitriptyline
4/14 and placebo 0/13
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk As reported: ’Patients were randomly as-
signed’
Allocation concealment (selection bias) Unclear risk No data
Blinding (performance bias and detection
bias)
of participants
Low risk As reported: ’All patients received 4 iden-
tical capsules daily: patients and staff were
blind’
Blinding (performance bias and detection
bias)
of personnel
Low risk As reported: ’All patients received 4 iden-
tical capsules daily: patients and staff were
blind’
Blinding (performance bias and detection
bias)
of outcome assessors
Unclear risk No data
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk None
Selective reporting (reporting bias) Unclear risk No protocol available. Generally accepted
outcomes have been used
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Spiker 1988 (Continued)
Other bias High risk Participants were retrospectively re-diag-
nosed. Psychotic depression and non-psy-
chotic depression were included and ran-
domly assigned. We used the data about
psychotic participants
14 days drug-free period (20% remission
with no further data) + one week placebo
before random assignment could be due to
low placebo response
van den Broek 2004
Methods Randomised, double-blind comparison
Participants DSM-IV diagnosis major depressive disorder; assessed with the depression part of the
SADS
HRSD-17 > 16
Inpatients; subgroup of psychotic depression
39% of all included participants were pretreated with an SSRI and 22.7% with a TCA,
but none as inpatients with adequate plasma level for at least four weeks during the
present episode
Interventions Imipramine versus fluvoxamine
Four days placebo washout
Predefined blood levels. Imipramine 150 to 450 mg (blood level imipramine + des-
imipramine 192 to 521). Fluvoxamine 150 to 1800 mg (blood level 109 to 325 ng/
mL). Treatment period: four weeks after reaching predefined blood levels. Additional
medication: one to six tablets a day containing 45 mg of an extract of valerian, lorazepam
1 to 3 mg a day or haloperidol 1 to 10 mg a day
Outcomes Dichotomous data: author defined: Response is reduction of HRSD-17 ≥ 50%. Remis-
sion is HRSD-17 < 8
Notes Subgroup with psychotic features. Some participants in this subgroup had been treated
with haloperidol (by us counted as dropouts). Worse responding in a group leads to
more participants who were given haloperidol
We used additional psychotic subgroup data from the author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk As reported: ’A computer generated randomi-
sation list was used’
Allocation concealment (selection bias) Unclear risk No specific data
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van den Broek 2004 (Continued)
Blinding (performance bias and detection
bias)
of participants
Low risk As reported: ’Tablets identical in appearance,
weight and taste were administered. Prepa-
ration of the tablets was done by the phar-
macist. The treating physician received blood
level data in percentages’
Blinding (performance bias and detection
bias)
of personnel
Low risk As reported: ’Tablets identical in appearance,
weight and taste were administered. Prepa-
ration of the tablets was done by the phar-
macist. The treating physician received blood
level data in percentage’
Blinding (performance bias and detection
bias)
of outcome assessors
Low risk As reported: ’The treating physicians were not
involved in the ratings’
Incomplete outcome data (attrition bias)
All outcomes
Low risk None
Selective reporting (reporting bias) Unclear risk No protocol available. Generally accepted
outcomes have been used
Other bias High risk Worse responding in a group leads to more
participants who were given haloperidol
We reanalyzed the data: Participants treated
with haloperidol were counted as dropouts
Wijkstra 2010
Methods Randomised double-blind study
Participants DSM-IV-defined psychotic depression
Inpatients
Interventions Seven weeks of treatment with imipramine (plasma levels 200 to 300 µg/L), venlafaxine
(375 mg/d), venlafaxine + quetiapine (375 mg/d + 600 mg/d)
Outcomes Dichotomous data: author defined (response). Response is >= 50% decrease in HAM-D
17 scores from baseline to study endpoint, and a final HAM-D score <= 14. Remission is
HAMD <= 7 (not predefined)
Notes No quetiapine arm. Inclusion did not reach planned number (122 i.s.o. 155)
Relatively low dropout rate (22/122 = 18%)
Risk of bias
Bias Authors’ judgement Support for judgement
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Wijkstra 2010 (Continued)
Random sequence generation (selection
bias)
Low risk As reported: ’Randomisation was executed centrally
using a computer-generated randomisation list: ran-
domly permuted blocks of size six’
Allocation concealment (selection bias) Low risk As reported: ’Randomisation was executed centrally’
Blinding (performance bias and detection
bias)
of participants
Low risk The study was double-blind. Blood was collected
from each participant (only imipramine blood level
was assessed). Treatment guesses were analysed and
indicated high preservation of blindness
Blinding (performance bias and detection
bias)
of personnel
Low risk Double-blind study. Blood was collected from each
participant (only imipramine blood level was as-
sessed). Treatment guesses were analysed and indi-
cated high preservation of blindness
Blinding (performance bias and detection
bias)
of outcome assessors
Low risk As reported: ’Blindness was checked and high. All
dose adjustments were done centrally by an indepen-
dent psychiatrist’
Incomplete outcome data (attrition bias)
All outcomes
Low risk None
Selective reporting (reporting bias) Low risk Protocol available. Generally accepted outcomes
have been used
Other bias Unclear risk 122 participants included i.s.o. with the planned 155
resulting in loss of power
Post hoc remission as secondary outcome measure
Zanardi 1996
Methods Randomised, double-blind comparison
Participants The SCID patient version was used for some participants but not for all (reply of author
to letter to editor)
DSM-III-R criteria; psychotic depressive episode
No HRSD criteria described at inclusion
Inpatients
No data about prior treatment of current episode
Interventions Sertraline versus paroxetine
Dose: 150 mg versus 50 mg from day 8
Blood levels: unknown
Additional medication: flurazepam < 30 mg (bipolar participants additional medication
lithium; bipolar participants are excluded from our data)
One week medication free (single-blind placebo period)
Treatment period: five weeks
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Zanardi 1996 (Continued)
Outcomes Dichotomous data: author defined: Response is HRSD-21 < 8 + DDERS (Dimensions
of Delusional Experience RS) = 0. Remission data not specified
Continuous data: symptom reduction: no data; global response: no data; QOL: no data
Overall dropout rate: yes
Dropout due to adverse effects: same as overall dropout
Mortality rate: 0
Notes 5/14 dropouts in paroxetine group and 0/18 in sertraline group
Bipolar participants could be excluded from our analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk As reported: ’Patients were randomly assigned
to two therapy groups’
Allocation concealment (selection bias) Unclear risk No data
Blinding (performance bias and detection
bias)
of participants
Unclear risk As reported: ’Patients were randomly as-
signed’. In title and abstract: ’Double-blind
controlled trial. No information about meth-
ods of blinding’
Blinding (performance bias and detection
bias)
of personnel
Unclear risk As reported: ’Double-blind controlled trial’
Blinding (performance bias and detection
bias)
of outcome assessors
Unclear risk No data
Incomplete outcome data (attrition bias)
All outcomes
Low risk None
Selective reporting (reporting bias) Unclear risk No protocol available. Generally accepted
outcomes have been used
Other bias Unclear risk We reanalyzed the data by excluding bipolar
participants
Difference in dropout is high: 5/14 versus 0/
18
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Zanardi 2000
Methods Randomised, double-blind comparison
Participants Unclear diagnosing procedure
DSM-IV criteria; psychotic depressive episode
No HRSD criteria described at inclusion
Inpatients
No data about prior treatment of current episode
Interventions Venlafaxine versus fluvoxamine
Dose: 300 mg versus 300 mg from day 8
Blood levels: unknown
Additional medication: flurazepam < 30 mg
One week medication free (single-blind placebo period)
Treatment period: five weeks
Outcomes Dichotomous data: author defined: Response is HRSD-21 < 9 + DDERS (Dimensions
of Delusional Experience RS) = 0. Remission data not specified
Continuous data: symptom reduction: no ITT data; global response: no ITT data; QOL:
no data
Overall dropout rate: yes
Dropout due to adverse effects: same as overall dropout rate
Mortality rate: 0
Notes We used additional data from the author to exclude the bipolar participants from the
analysis
Included 22 participants with major depressive disorder (MDD) with psychotic fea-
tures. Responders in venlafaxine group 6/11 MDD. Responders fluvoxamine group 9/
11 MDD. No dropouts in fluvoxamine group. Two dropouts in venlafaxine group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk As reported: ’Randomization was performed
by a computer-generated schedule’
Allocation concealment (selection bias) Unclear risk Randomisation method not described
Blinding not explicitly described. No data
Blinding (performance bias and detection
bias)
of participants
Unclear risk As reported: ’Patients were randomly as-
signed’
’Double-blind controlled study’
Blinding (performance bias and detection
bias)
of personnel
Unclear risk ’Double-blind controlled study’, but unclear
whether double-blind includes personnel
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Zanardi 2000 (Continued)
Blinding (performance bias and detection
bias)
of outcome assessors
Low risk As reported: ’Raters were blind to treatment’
Incomplete outcome data (attrition bias)
All outcomes
Low risk None
Selective reporting (reporting bias) Unclear risk No protocol available. Generally accepted
outcomes have been used
Other bias Unclear risk We reanalyzed the data by excluding bipolar
participants with additional data from the au-
thor
DSM: Diagnostic and Statistical Manual of Mental Disorders.
HRSD/HAM-D: Hamilton Rating Scale for Depression.
ITT: Intention-to-Treat.
LOCF: Last Observation Carried Forward.
MDD: Major Depressive Disorder.
QOL: Quality of Life.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Belanoff 2001 Only four days of treatment
Bellini 1994 25% bipolar participants (in each group three bipolar participants)
The author did not respond to our request for additional information
Blasey 2009 Impossible to compare two defined pharmacological treatments
Blasey 2011 Impossible to compare two defined pharmacological treatments
Cassacchia 1984 ’Unipolar psychotic depression’ is probably ’manic depressive psychosis, depressive type’ (ICD9). This is not the
same as ’psychotic depression’
Number of bipolar participants is not clear
Dropouts not in results. It is not possible to extract ITT response data
Reason for exclusion: unclear diagnosis, number of bipolar participants unclear, ITT data not available
Davidson 1981 Reason for exclusion: unclear diagnosis and short treatment period
DeBattista 2006 Impossible to compare two defined pharmacological treatments. 48.3% + 12.9% = 61.2% HAMD response
with placebo after one week
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(Continued)
Ebert 1997 Randomisation not adequate, open study
Flores 2006 Impossible to compare two defined pharmacological treatments and treatment only seven days
Friedman 1966 No comparable diagnostic procedure. No data about MDD subgroup
Dropouts have been excluded
Künzel 2008 No ITT data; bipolar participants 17.5% in per-protocol data; continued treatment with lithium, valproic acid
Malison 1999 Only three psychotic participants
McLaughlin 1969 Diagnosis unclear
Müller 1998 In this subgroup, no data are given about responders, bipolar participants and dropouts
The author did not respond to our request for additional information
Navarro 2001 Citalopram versus nortriptyline
Subgroup with nine psychotic depressive episodes
Reason for exclusion: This subgroup was also treated with haloperidol. No data available about this subgroup
The author did not respond to our request for additional information
Nelson 1984 Unknown fromdata in which group the responders are located (imipramine or ami). So comparison is impossible
Spiker 1982 Pre-published data from the 1985 study
Zanardi 1998 30.5 % bipolar participants
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D A T A A N D A N A L Y S E S
Comparison 1. Antidepressant versus placebo




participants Statistical method Effect size
1 Clinical response 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Amitriptyline versus
placebo
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Dropouts 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Amitriptyline versus
placebo
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Antipsychotic versus placebo




participants Statistical method Effect size
1 Clinical response 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Olanzapine versus placebo 2 201 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.74, 1.73]
2 Dropouts 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Olanzapine versus placebo 2 201 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.57, 1.08]
Comparison 3. Antidepressant versus antidepressant




participants Statistical method Effect size
1 Clinical response 5 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Imipramine versus
venlafaxine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.2 Imipramine versus
mirtazapine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 Imipramine versus
fluvoxamine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.4 Fluvoxamine versus
venlafaxine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.5 Sertraline versus
paroxetine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Dropouts 5 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Imipramine versus
venlafaxine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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2.2 Imipramine versus
mirtazapine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 Imipramine versus
fluvoxamine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.4 Fluvoxamine versus
venlafaxine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.5 Sertraline versus
paroxetine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 4. Antidepressant versus antipsychotic




participants Statistical method Effect size
1 Clinical response 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Amitriptyline versus
perphenazine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Dropouts 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Amitriptyline versus
perphenazine
1 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Antidepressant plus antipsychotic versus placebo




participants Statistical method Effect size
1 Clinical response 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Fluoxetine + olanzapine
versus placebo
2 148 Risk Ratio (M-H, Fixed, 95% CI) 1.86 [1.23, 2.82]
2 Dropouts 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Fluoxetine + olanzapine
versus placebo
2 148 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.48, 1.18]
Comparison 6. Antidepressant plus antipsychotic versus placebo plus antipsychotic




participants Statistical method Effect size




1 39 Risk Ratio (M-H, Fixed, 95% CI) 3.61 [1.23, 10.56]
1.2 Fluoxetine + olanzapine
versus olanzapine
2 149 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [1.10, 2.44]
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1.3 Olanzapine + sertraline
versus olanzapine
1 259 Risk Ratio (M-H, Fixed, 95% CI) 1.76 [1.21, 2.54]




1 39 Risk Ratio (M-H, Fixed, 95% CI) 3.09 [0.38, 25.19]
2.2 Fluoxetine + olanzapine
versus olanzapine
2 149 Risk Ratio (M-H, Fixed, 95% CI) 0.95 [0.59, 1.53]
2.3 Olanzapine + sertraline
versus olanzapine
1 259 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.53, 0.92]
Comparison 7. Antidepressant plus antipsychotic versus placebo plus antidepressant




participants Statistical method Effect size




1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.49, 2.53]
1.2 Venlafaxine + quetiapine
versus venlafaxine




1 41 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [0.89, 3.37]
1.4 Amitriptyline +
perphenazine versus amoxapine
1 46 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.75, 1.88]
1.5 Venlafaxine + quetiapine
versus imipramine
1 63 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.84, 1.93]




1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.26, 4.81]
2.2 Venlafaxine + quetiapine
versus venlafaxine




1 41 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [0.35, 8.41]
2.4 Amitriptyline +
perphenazine versus amoxapine
1 46 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.29, 1.45]
2.5 Venlafaxine + quetiapine
versus imipramine
1 63 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.38, 3.47]
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Comparison 8. Antidepressant plus antipsychotic versus placebo plus the same antidepressant




participants Statistical method Effect size




1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.49, 2.53]
1.2 Venlafaxine + quetiapine
versus venlafaxine




1 41 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [0.89, 3.37]




1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.26, 4.81]
2.2 Venlafaxine + quetiapine
versus venlafaxine




1 41 Risk Ratio (M-H, Fixed, 95% CI) 1.73 [0.35, 8.41]
Analysis 1.1. Comparison 1 Antidepressant versus placebo, Outcome 1 Clinical response.
Review: Pharmacological treatment for psychotic depression
Comparison: 1 Antidepressant versus placebo
Outcome: 1 Clinical response
Study or subgroup Antidepressant Placebo Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Amitriptyline versus placebo
Spiker 1988 4/14 0/13 8.40 [ 0.50, 142.27 ]
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours antidepressant
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Analysis 1.2. Comparison 1 Antidepressant versus placebo, Outcome 2 Dropouts.
Review: Pharmacological treatment for psychotic depression
Comparison: 1 Antidepressant versus placebo
Outcome: 2 Dropouts
Study or subgroup Placebo Antidepressant Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Amitriptyline versus placebo
Spiker 1988 3/13 4/14 0.81 [ 0.22, 2.94 ]
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours antidepressant
Analysis 2.1. Comparison 2 Antipsychotic versus placebo, Outcome 1 Clinical response.
Review: Pharmacological treatment for psychotic depression
Comparison: 2 Antipsychotic versus placebo
Outcome: 1 Clinical response
Study or subgroup Antipsychotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Olanzapine versus placebo
Rothschild 2004a 15/48 14/51 48.3 % 1.14 [ 0.62, 2.10 ]
Rothschild 2004b 17/53 14/49 51.7 % 1.12 [ 0.62, 2.03 ]
Subtotal (95% CI) 101 100 100.0 % 1.13 [ 0.74, 1.73 ]
Total events: 32 (Antipsychotic), 28 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours antipsychotic
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Analysis 2.2. Comparison 2 Antipsychotic versus placebo, Outcome 2 Dropouts.
Review: Pharmacological treatment for psychotic depression
Comparison: 2 Antipsychotic versus placebo
Outcome: 2 Dropouts
Study or subgroup Antipsychotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Olanzapine versus placebo
Rothschild 2004a 13/48 19/51 38.8 % 0.73 [ 0.40, 1.31 ]
Rothschild 2004b 25/53 28/49 61.2 % 0.83 [ 0.57, 1.20 ]
Subtotal (95% CI) 101 100 100.0 % 0.79 [ 0.57, 1.08 ]
Total events: 38 (Antipsychotic), 47 (Placebo)
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours antipsychotic Favours placebo
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Analysis 3.1. Comparison 3 Antidepressant versus antidepressant, Outcome 1 Clinical response.
Review: Pharmacological treatment for psychotic depression
Comparison: 3 Antidepressant versus antidepressant
Outcome: 1 Clinical response
Study or subgroup Experimental AD Comparator AD Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Imipramine versus venlafaxine
Wijkstra 2010 22/42 13/39 1.57 [ 0.93, 2.67 ]
2 Imipramine versus mirtazapine
Bruijn 1996 9/15 3/15 3.00 [ 1.01, 8.95 ]
3 Imipramine versus fluvoxamine
van den Broek 2004 16/25 7/23 2.10 [ 1.06, 4.17 ]
4 Fluvoxamine versus venlafaxine
Zanardi 2000 9/11 6/11 1.50 [ 0.82, 2.75 ]
5 Sertraline versus paroxetine
Zanardi 1996 13/18 3/14 3.37 [ 1.19, 9.57 ]
0.1 0.2 0.5 1 2 5 10
Favours experimental AD Favours comparator AD
51Pharmacological treatment for psychotic depression (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.2. Comparison 3 Antidepressant versus antidepressant, Outcome 2 Dropouts.
Review: Pharmacological treatment for psychotic depression





AD Comparator AD Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Imipramine versus venlafaxine
Wijkstra 2010 7/42 8/39 0.81 [ 0.33, 2.03 ]
2 Imipramine versus mirtazapine
Bruijn 1996 4/15 8/15 0.50 [ 0.19, 1.31 ]
3 Imipramine versus fluvoxamine
van den Broek 2004 4/25 2/25 2.00 [ 0.40, 9.95 ]
4 Fluvoxamine versus venlafaxine
Zanardi 2000 0/11 2/11 0.20 [ 0.01, 3.74 ]
5 Sertraline versus paroxetine
Zanardi 1996 0/18 5/14 0.07 [ 0.00, 1.20 ]
0.1 0.2 0.5 1 2 5 10
Favours experimental AD Favours comparator AD
Analysis 4.1. Comparison 4 Antidepressant versus antipsychotic, Outcome 1 Clinical response.
Review: Pharmacological treatment for psychotic depression
Comparison: 4 Antidepressant versus antipsychotic
Outcome: 1 Clinical response
Study or subgroup Antidepressant Antipsychotic Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Amitriptyline versus perphenazine
Spiker 1985 7/19 3/17 2.09 [ 0.64, 6.82 ]
0.1 0.2 0.5 1 2 5 10
Favours antipsychotic Favours antidepressant
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Analysis 4.2. Comparison 4 Antidepressant versus antipsychotic, Outcome 2 Dropouts.
Review: Pharmacological treatment for psychotic depression
Comparison: 4 Antidepressant versus antipsychotic
Outcome: 2 Dropouts
Study or subgroup Antidepressant Antipsychotic Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Amitriptyline versus perphenazine
Spiker 1985 2/19 1/17 1.79 [ 0.18, 18.02 ]
0.1 0.2 0.5 1 2 5 10
Favours antidepressant Favours antipsychotic
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Analysis 5.1. Comparison 5 Antidepressant plus antipsychotic versus placebo, Outcome 1 Clinical response.
Review: Pharmacological treatment for psychotic depression
Comparison: 5 Antidepressant plus antipsychotic versus placebo




antipsychotic Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fluoxetine + olanzapine versus placebo
Rothschild 2004a 14/25 14/51 50.7 % 2.04 [ 1.16, 3.59 ]
Rothschild 2004b 11/23 14/49 49.3 % 1.67 [ 0.91, 3.10 ]
Subtotal (95% CI) 48 100 100.0 % 1.86 [ 1.23, 2.82 ]
Total events: 25 (antidepressant plus antipsychotic), 28 (Placebo)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.92 (P = 0.0035)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours placebo antidepressant plus antipsychotic
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Analysis 5.2. Comparison 5 Antidepressant plus antipsychotic versus placebo, Outcome 2 Dropouts.
Review: Pharmacological treatment for psychotic depression





antipsychotic placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Fluoxetine + olanzapine versus placebo
Rothschild 2004a 11/25 19/51 41.1 % 1.18 [ 0.67, 2.08 ]
Rothschild 2004b 6/23 28/49 58.9 % 0.46 [ 0.22, 0.95 ]
Subtotal (95% CI) 48 100 100.0 % 0.75 [ 0.48, 1.18 ]
Total events: 17 (antidepressant plus antipsychotic), 47 (placebo)
Heterogeneity: Chi2 = 4.21, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.24 (P = 0.21)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours AD + AP Favours placebo
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Analysis 6.1. Comparison 6 Antidepressant plus antipsychotic versus placebo plus antipsychotic, Outcome
1 Clinical response.
Review: Pharmacological treatment for psychotic depression
Comparison: 6 Antidepressant plus antipsychotic versus placebo plus antipsychotic
Outcome: 1 Clinical response
Study or subgroup AP + AD AP + Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 amitriptyline + perphenazine versus perphenazine
Spiker 1985 14/22 3/17 6.2 % 3.61 [ 1.23, 10.56 ]
Subtotal (95% CI) 22 17 6.2 % 3.61 [ 1.23, 10.56 ]
Total events: 14 (AP + AD), 3 (AP + Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
2 Fluoxetine + olanzapine versus olanzapine
Rothschild 2004a 14/25 15/48 18.7 % 1.79 [ 1.04, 3.09 ]
Rothschild 2004b 11/23 17/53 18.8 % 1.49 [ 0.84, 2.66 ]
Subtotal (95% CI) 48 101 37.5 % 1.64 [ 1.10, 2.44 ]
Total events: 25 (AP + AD), 32 (AP + Placebo)
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
3 Olanzapine + sertraline versus olanzapine
Meyers 2009 54/129 31/130 56.3 % 1.76 [ 1.21, 2.54 ]
Subtotal (95% CI) 129 130 56.3 % 1.76 [ 1.21, 2.54 ]
Total events: 54 (AP + AD), 31 (AP + Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.99 (P = 0.0028)
Total (95% CI) 199 248 100.0 % 1.83 [ 1.40, 2.38 ]
Total events: 93 (AP + AD), 66 (AP + Placebo)
Heterogeneity: Chi2 = 2.06, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 4.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.82, df = 2 (P = 0.40), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours AP + placebo Favours AP + AD
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Analysis 6.2. Comparison 6 Antidepressant plus antipsychotic versus placebo plus antipsychotic, Outcome
2 Dropouts.
Review: Pharmacological treatment for psychotic depression
Comparison: 6 Antidepressant plus antipsychotic versus placebo plus antipsychotic
Outcome: 2 Dropouts
Study or subgroup AP + AD AP + placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Amitriptyline + perphenazine versus perphenazine
Spiker 1985 4/22 1/17 1.2 % 3.09 [ 0.38, 25.19 ]
Subtotal (95% CI) 22 17 1.2 % 3.09 [ 0.38, 25.19 ]
Total events: 4 (AP + AD), 1 (AP + placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 Fluoxetine + olanzapine versus olanzapine
Rothschild 2004a 11/25 13/48 9.5 % 1.62 [ 0.86, 3.08 ]
Rothschild 2004b 6/23 25/53 16.1 % 0.55 [ 0.26, 1.16 ]
Subtotal (95% CI) 48 101 25.6 % 0.95 [ 0.59, 1.53 ]
Total events: 17 (AP + AD), 38 (AP + placebo)
Heterogeneity: Chi2 = 4.72, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.21 (P = 0.83)
3 Olanzapine + sertraline versus olanzapine
Meyers 2009 48/129 69/130 73.2 % 0.70 [ 0.53, 0.92 ]
Subtotal (95% CI) 129 130 73.2 % 0.70 [ 0.53, 0.92 ]
Total events: 48 (AP + AD), 69 (AP + placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.52 (P = 0.012)
Total (95% CI) 199 248 100.0 % 0.79 [ 0.63, 1.01 ]
Total events: 69 (AP + AD), 108 (AP + placebo)
Heterogeneity: Chi2 = 8.09, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 1.91 (P = 0.056)
Test for subgroup differences: Chi2 = 2.88, df = 2 (P = 0.24), I2 =31%
0.1 0.2 0.5 1 2 5 10
Favours AP + AD Favours AP + placebo
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Analysis 7.1. Comparison 7 Antidepressant plus antipsychotic versus placebo plus antidepressant, Outcome
1 Clinical response.
Review: Pharmacological treatment for psychotic depression
Comparison: 7 Antidepressant plus antipsychotic versus placebo plus antidepressant
Outcome: 1 Clinical response
Study or subgroup AD + AP AD + Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nortriptyline + perphenazine versus nortriptyline
Mulsant 2001 7/17 7/19 13.1 % 1.12 [ 0.49, 2.53 ]
Subtotal (95% CI) 17 19 13.1 % 1.12 [ 0.49, 2.53 ]
Total events: 7 (AD + AP), 7 (AD + Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
2 Venlafaxine + quetiapine versus venlafaxine
Wijkstra 2010 13/20 13/39 17.4 % 1.95 [ 1.13, 3.37 ]
Subtotal (95% CI) 20 39 17.4 % 1.95 [ 1.13, 3.37 ]
Total events: 13 (AD + AP), 13 (AD + Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
3 Amitriptyline + perphenazine versus amitriptyline
Spiker 1985 14/22 7/19 14.8 % 1.73 [ 0.89, 3.37 ]
Subtotal (95% CI) 22 19 14.8 % 1.73 [ 0.89, 3.37 ]
Total events: 14 (AD + AP), 7 (AD + Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
4 Amitriptyline + perphenazine versus amoxapine
Anton 1990 17/25 12/21 25.8 % 1.19 [ 0.75, 1.88 ]
Subtotal (95% CI) 25 21 25.8 % 1.19 [ 0.75, 1.88 ]
Total events: 17 (AD + AP), 12 (AD + Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.74 (P = 0.46)
5 Venlafaxine + quetiapine versus imipramine
Wijkstra 2010 14/21 22/42 29.0 % 1.27 [ 0.84, 1.93 ]
Subtotal (95% CI) 21 42 29.0 % 1.27 [ 0.84, 1.93 ]
Total events: 14 (AD + AP), 22 (AD + Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Total (95% CI) 105 140 100.0 % 1.42 [ 1.11, 1.80 ]
Total events: 65 (AD + AP), 61 (AD + Placebo)
Heterogeneity: Chi2 = 2.78, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.83 (P = 0.0047)
Test for subgroup differences: Chi2 = 2.76, df = 4 (P = 0.60), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours AD + placebo Favours AD + AP
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Analysis 7.2. Comparison 7 Antidepressant plus antipsychotic versus placebo plus antidepressant, Outcome
2 Dropouts.
Review: Pharmacological treatment for psychotic depression
Comparison: 7 Antidepressant plus antipsychotic versus placebo plus antidepressant
Outcome: 2 Dropouts
Study or subgroup AD + AP AD + placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nortriptyline + perphenazine versus nortriptyline
Mulsant 2001 3/17 3/19 11.4 % 1.12 [ 0.26, 4.81 ]
Subtotal (95% CI) 17 19 11.4 % 1.12 [ 0.26, 4.81 ]
Total events: 3 (AD + AP), 3 (AD + placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 Venlafaxine + quetiapine versus venlafaxine
Wijkstra 2010 3/20 8/39 21.8 % 0.73 [ 0.22, 2.46 ]
Subtotal (95% CI) 20 39 21.8 % 0.73 [ 0.22, 2.46 ]
Total events: 3 (AD + AP), 8 (AD + placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
3 Amitriptyline + perphenazine versus amitriptyline
Spiker 1985 4/22 2/19 8.6 % 1.73 [ 0.35, 8.41 ]
Subtotal (95% CI) 22 19 8.6 % 1.73 [ 0.35, 8.41 ]
Total events: 4 (AD + AP), 2 (AD + placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
4 Amitriptyline + perphenazine versus amoxapine
Anton 1990 7/25 9/21 39.4 % 0.65 [ 0.29, 1.45 ]
Subtotal (95% CI) 25 21 39.4 % 0.65 [ 0.29, 1.45 ]
Total events: 7 (AD + AP), 9 (AD + placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
5 Venlafaxine + quetiapine versus imipramine
Wijkstra 2010 4/21 7/42 18.8 % 1.14 [ 0.38, 3.47 ]
Subtotal (95% CI) 21 42 18.8 % 1.14 [ 0.38, 3.47 ]
Total events: 4 (AD + AP), 7 (AD + placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 105 140 100.0 % 0.91 [ 0.55, 1.50 ]
0.1 0.2 0.5 1 2 5 10
Favours AD + AP Favours AD + placebo
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(. . . Continued)
Study or subgroup AD + AP AD + placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 21 (AD + AP), 29 (AD + placebo)
Heterogeneity: Chi2 = 1.65, df = 4 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.71)
Test for subgroup differences: Chi2 = 1.64, df = 4 (P = 0.80), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours AD + AP Favours AD + placebo
Analysis 8.1. Comparison 8 Antidepressant plus antipsychotic versus placebo plus the same antidepressant,
Outcome 1 Clinical response.
Review: Pharmacological treatment for psychotic depression
Comparison: 8 Antidepressant plus antipsychotic versus placebo plus the same antidepressant
Outcome: 1 Clinical response
Study or subgroup AD + AP AD + Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nortriptyline + perphenazine versus nortriptyline
Mulsant 2001 7/17 7/19 24.1 % 1.12 [ 0.49, 2.53 ]
Subtotal (95% CI) 17 19 24.1 % 1.12 [ 0.49, 2.53 ]
Total events: 7 (AD + AP), 7 (AD + Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
2 Venlafaxine + quetiapine versus venlafaxine
Wijkstra 2010 27/41 13/39 48.5 % 1.98 [ 1.20, 3.24 ]
Subtotal (95% CI) 41 39 48.5 % 1.98 [ 1.20, 3.24 ]
Total events: 27 (AD + AP), 13 (AD + Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.69 (P = 0.0071)
3 Amitriptyline + perphenazine versus amitriptyline
Spiker 1985 14/22 7/19 27.4 % 1.73 [ 0.89, 3.37 ]
Subtotal (95% CI) 22 19 27.4 % 1.73 [ 0.89, 3.37 ]
Total events: 14 (AD + AP), 7 (AD + Placebo)
Heterogeneity: not applicable
0.1 0.2 0.5 1 2 5 10
Favours AD + placebo Favours AD + AP
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(. . . Continued)
Study or subgroup AD + AP AD + Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.60 (P = 0.11)
Total (95% CI) 80 77 100.0 % 1.70 [ 1.19, 2.43 ]
Total events: 48 (AD + AP), 27 (AD + Placebo)
Heterogeneity: Chi2 = 1.36, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
Test for subgroup differences: Chi2 = 1.36, df = 2 (P = 0.51), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours AD + placebo Favours AD + AP
Analysis 8.2. Comparison 8 Antidepressant plus antipsychotic versus placebo plus the same antidepressant,
Outcome 2 Dropouts.
Review: Pharmacological treatment for psychotic depression
Comparison: 8 Antidepressant plus antipsychotic versus placebo plus the same antidepressant
Outcome: 2 Dropouts
Study or subgroup AD + AP AD + placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Nortriptyline + perphenazine versus nortriptyline
Mulsant 2001 3/17 3/19 21.5 % 1.12 [ 0.26, 4.81 ]
Subtotal (95% CI) 17 19 21.5 % 1.12 [ 0.26, 4.81 ]
Total events: 3 (AD + AP), 3 (AD + placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.15 (P = 0.88)
2 Venlafaxine + quetiapine versus venlafaxine
Wijkstra 2010 7/41 8/39 62.2 % 0.83 [ 0.33, 2.08 ]
Subtotal (95% CI) 41 39 62.2 % 0.83 [ 0.33, 2.08 ]
Total events: 7 (AD + AP), 8 (AD + placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.69)
3 Amitriptyline + perphenazine versus amitriptyline
Spiker 1985 4/22 2/19 16.3 % 1.73 [ 0.35, 8.41 ]
Subtotal (95% CI) 22 19 16.3 % 1.73 [ 0.35, 8.41 ]
0.1 0.2 0.5 1 2 5 10
Favours AD + AP Favours AD + placebo
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(. . . Continued)
Study or subgroup AD + AP AD + placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 4 (AD + AP), 2 (AD + placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Total (95% CI) 80 77 100.0 % 1.04 [ 0.52, 2.07 ]
Total events: 14 (AD + AP), 13 (AD + placebo)
Heterogeneity: Chi2 = 0.63, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.11 (P = 0.91)
Test for subgroup differences: Chi2 = 0.63, df = 2 (P = 0.73), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours AD + AP Favours AD + placebo
A P P E N D I C E S
Appendix 1. CENTRAL update search 2010
The Cochrane Register of Controlled Trails (CENTRAL) was searched (Issue 4, 2010) using the following terms:
#1 MeSH descriptor DEPRESSION, this term only
#2 MeSH descriptor DEPRESSIVE DISORDER, this term only
#3 MeSH descriptor DEPRESSIVE DISORDER MAJOR, this term only
#4 (depression* or depressive*):ti,ab,kw
#5 (#1 or #2 or #3 or #4)
#6 MeSH descriptor DELUSIONS, this term only
#7 delusion*:ti,ab,kw
#8 MeSH descriptor PSYCHOTIC DISORDERS, this term only
#9 MeSH AFFECTIVE DISORDERS, PSYCHOTIC, this term only
#10 (psychotic* or psychosis or psychoses) :ti,ab,kw
#11 (#6 or #7 or #8 or #9 or #10)
#12 (#5 and #11), from 2005 to 2010
#13 SR-DEPRESSN or HS-DEPRESSN
#14 (#12 NOT #13)
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Appendix 2. Previous search strategies to 2005
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) with the terms depressive disorder and drug treatment. In
addition we searchedMEDLINE (1966 until April 2004) and EMBASE (1980 until April 2004) using the following terms: (“depressive
disorder/drug therapy”[MESH] AND ((“delusions”[MESH Terms] OR delusions[Text Word]) OR ((“psychotic disorders”[MESH
Terms] OR psychotic[Text Word]) AND features[All Fields])))) combined with a sensitive search strategy for RCTs.
F E E D B A C K
Feedback submitted, 3 February 2015
Summary
We found a possible error in the review ’Pharmacological treatment for psychotic depression’ byWijkstra J, Lijmer J, Burger H, Geddes
J, Nolen WA., which was published in issue 11 of year 2013.
When we read through the review, we found that they included 2 comparisons from a single article to calculate clinical outcome in their
Analysis 7. The referenced article was Wijkstra 2010, in which 122 patients were randomized into 3 treatment groups; imipramine (n=
42), venlafaxine (n=39) or venlafaxine + quetiapine (n=41). In their Analysis 7, they compared imipramine or venlafaxine group against
venlafaxine + quetiapine group independently in each subgroup. Then, when they conducted the analysis for the Total, venlafaxine +
quetiapine group (n=41) was included twice in the “antidepressant plus antipsychotic” group.
Double counting the same subjects would spuriously increase precision in the meta-analytic estimates. Authors should use a proper
method to avoid double-counting the same subjects.
Reply
We would like to thank Dr Matsuo and his colleagues for pointing out this mistake in the original analysis. We looked at this and
we agreed that the best approach is probably to split the comparator (as described in the Cochrane Handbook, chapter 16.5.4). We
amended the analyses in the revised review accordingly and, given the numbers involved, it makes no material difference to the point
estimates or precision. The revised estimate for clinical response (see Analysis 7.1) was: RR 1.42; 95% CI 1.11 to 1.81 (while the
original pooled RR was 1.44 with a 95% CI 1.15 to 1.80). The revised estimate for dropouts (see Analysis 7.2) was: RR 0.91, 95% CI
0.55 to 1.50 (the original pooled RR was 0.91, with a 95% CI 0.58 to 1.44).
We thank the EBMH Study Group for their interest and close reading of our review.
Contributors
Feedback submitted by: Masahiro Matsuo, Aran Tajika, Toshi A. Furukawa, Kyoto EBMH Study Group
Response submitted by: Andrea Cipriani and John Geddes
WH A T ’ S N E W
Last assessed as up-to-date: 12 April 2013.
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Date Event Description
9 July 2015 Feedback has been incorporated Mistake in original analysis was corrected. This made no
material difference to the results
10 June 2013 New search has been performed Searches and methodology updated
10 June 2013 New citation required and conclusions have changed Update of previous review. Two new studies included; con-
clusions slightly revised
H I S T O R Y
Protocol first published: Issue 1, 2003
Review first published: Issue 4, 2005
Date Event Description
2 September 2010 Amended Methods updated to reflect current Handbook
3 November 2008 Amended Converted to new review format.
10 August 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
J Wijkstra: development of protocol, coordination and writing of the review, data collection, analysis, primary author report.
J Lijmer: development of protocol, data collection, analysis, co-author report.
H Burger: statistical advice.
J Geddes: co-author report.
WA Nolen: development of protocol, data collection, analysis, overall supervision, co-author report.
A Cipriani: statistical advice and analysis.
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D E C L A R A T I O N S O F I N T E R E S T
JW and WN conducted a multi-centre trial in participants with psychotic depression that compared treatment with imipramine,
venlafaxine and venlafaxine plus quetiapine. Wyeth and AstraZeneca financially supported this trial. Data from this trial are included
in this review. To prevent bias, the data extracted from our own study explicitly have been checked by the Cochrane organisation.
JG has received research funding and support from sanofi-aventis and GlaxoSmithKline and is currently in discussion with several other
companies that manufacture SSRIs about collaboration on planned independent trials and systematic reviews.
This review has been undertaken without external support.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
All studies were evaluated according to the new method used for assessing risk of bias. The background section has been updated.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antidepressive Agents [∗therapeutic use]; Antipsychotic Agents [∗therapeutic use]; DepressiveDisorder,Major [∗drug therapy; etiology];
Drug Therapy, Combination [methods]; Psychotic Disorders [complications; ∗drug therapy]; Randomized Controlled Trials as Topic
MeSH check words
Humans
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